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The aim of this thesis by prospective publication was to evaluate the comparative 
accuracy of screening technologies for the detection of COAG and other sight-
threatening eye diseases.  
It incorporates 4 peer-reviewed publications:  
1). Methodology and reporting of diagnostic accuracy studies of automated 
perimetry in glaucoma: evaluation using a standardised approach (Ophthalmic 
Physiol Opt. 2015; 35(3):315-23). This publication reported on an evaluation of the 
methodological and reporting quality of diagnostic accuracy studies of perimetry in 
glaucoma and determined whether there had been any improvement since the 
publication of the Standards for Reporting of Diagnostic. Accuracy (STARD) 
guidelines in 2003. The main findings were that methodological and reporting 
quality was sub-optimal and appeared not to have improved substantially following 
the development of the STARD guidance. 
2). Development and validation of a new glaucoma screening test using temporally 
modulated flicker (Ophthalmic Physiol Opt. 2018; 38(6):617-628). This publication 
described the psychometric characteristics and diagnostic accuracy of the 
Accelerator 4-Alternative Forced-Choice Flicker Test prototype (A4FTp) for 
detecting Chronic open angle glaucoma (COAG). The performance of the A4FTp 
was also compared with standard screening tests of ocular structure and function 
(Frequency Doubling Technology (FDT) perimetry and iVue Spectral Domain 
Optical Coherence Tomography (SD-OCT). The time taken to complete the A4FTp 
was relatively short and initial results are promising. The diagnostic accuracy for 
the A4FTp was comparable to those of the FDT and SD-OCT for detecting COAG 
and we concluded that with further refinement the A4FTp could have role in 
glaucoma detection in the future. 
3). Diagnostic accuracy of technologies for glaucoma case-finding in a community 
setting (Ophthalmology. 2015;122(12):2407-15). This publication described a 
cross-sectional, observational, community-based study to evaluate the diagnostic 
performance of the FDT, Moorfields Motion Displacement Test (MMDT), iVue SD-
OCT and ocular response analyzer (ORA) used alone or in combination, for the 
detection of COAG. Diagnostic performance of individual tests gave acceptable 
accuracy for COAG detection. The best performing parameter was inferior RNFL 
thickness recorded using the SD-OCT. Although the low specificity of visual-
11 
 
function tests precluded their use in isolation, an acceptable performance was 
achieved by combining RNFL thickness analysis with visual function tests 
4). Role of advanced technology in the detection of sight-threatening eye disease 
in a UK community setting (BMJ Open Ophthalmology 2019; 4:e000347). This 
publication extended the analysis described above to determine the performance 
of same screening tests for detecting sight-threatening eye disease in a cohort of 
elderly subjects recruited from primary care. The main finding was that a subset of 
screening tests (FDT, SD-OCT, together with a recorded visual acuity <6/12) was 
the most effective in detecting significant eye disease in this elderly population. 
The study provided useful preliminary data to inform the development of further 
larger, multi-center screening studies to validate this screening panel. 
The work described in this thesis makes a useful contribution to the evidence base 
on the use of imaging and visual function technologies to identify COAG and other 
sight-threatening eye diseases in at-risk populations and provides clear directions 
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Chapter 1.  
Introduction and Objectives 
1.1. Introduction 
Visual impairment is an escalating global public health problem. Population growth 
coupled with an increasingly longevity in most countries, has led to rising numbers 
of people with visual impairment. In 2017, a systematic review and meta-analysis 
of available data sources, estimated that 216·6 million of the world’s population 
was suffering from moderate or severe vision impairment (defined as visual acuity 
(VA) <6/18 but ≥3/60) with 36.0 million people blind (<3/60 in the better eye) 
(Flaxman et al 2017). The three leading causes of blindness were cataract, 
uncorrected refractive error, and glaucoma. In the case of moderate or severe 
vision impairment, main causes included; uncorrected refractive error, cataract, 
and age-related macular degeneration (AMD). Large regional variation in 
prevalence estimates were reported, with a higher prevalence of visual impairment 
due to AMD in high-income countries (Bunce et al 2015). 
In the UK, visual impairment and blindness affects approximately 2 million people 
(3% of the population) (Pezzulu et al 2018) and the overall health and social care 
costs associated with sight loss and blindness have been estimated at £15.8 billion 
per annum (Pezzullu et 2018). Given that a significant proportion of sight loss and 
blindness is preventable, further investment in prevention, early detection and 
timely intervention is likely to be an effective strategy to reduce the burden of visual 
disability and improve socioeconomic outcomes (WHO 2013).  
Glaucoma is a progressive optic neuropathy that can potentially lead to blindness 
if left untreated. In the UK, glaucoma remains the second most common cause of 
blindness and is responsible for 11% of cases of severe sight impairment 
(Quartilho et al 2016). Current models of detection of chronic open-angle glaucoma 
(COAG) rely on opportunistic case-finding and although there is evidence that in 
high-income countries at least 50% of cases remain undiagnosed (Klein et al 1992; 
Mitchell et al 1996), no country has so far introduced population screening for 
glaucoma. Health economic modelling studies conducted in Finland (Vaahtoranta-
Lehtonen et al 2007) and the UK (Hernandez et al 2008) have suggested that 
screening for COAG could be cost-effective for specific subgroups at higher risk.  
An ideal screening test for COAG should be quick, easy to perform and interpret, 
and be acceptable to the population being tested. It should also have sufficient 
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diagnostic power to distinguish between those who have and those who do not 
have COAG. There is currently a lack of high-quality diagnostic accuracy studies 
for COAG detection (Mowatt et al 2008; Michelessi et al 2015). Screening test 
accuracy is variable across studies and test performance is frequently 
overestimated due to the use of a case-control design that compares a healthy with 
a diseased population. Ideally, diagnostic accuracy studies should be carried out 
on patients selected consecutively at a defined stage of the clinical pathway. 
The overall aim of the studies described in this thesis is to evaluate the comparative 
accuracy of screening technologies for the detection of COAG and other sight-
threatening eye diseases. This includes an assessment of the methodological 
quality and adherence to reporting standards of existing diagnostic accuracy 
studies; the development and evaluation of a novel screening test for COAG that 
incorporates temporally modulated flicker and establishing the performance of a 
battery of conventional diagnostic tests for the detection of glaucoma and other 




1. To assess the methodological quality of diagnostic test accuracy studies of 
using the QUADAS 2003 tool (an evidence-based quality assessment tool) 
and evaluate the accuracy and completeness of reporting of these studies 
based on the Standards for Reporting Diagnostic Accuracy (STARD) 2003 
checklist (Chapter 2). 
2. To develop a new algorithm to determine flicker sensitivity thresholds in 
susceptible areas of the visual field (Accelerator 4-Alternative Forced-Choice 
Flicker Test prototype (A4FTp)) that could be used as a rapid screening test 
for COAG (Chapter 3) 
3. To evaluate the psychometric properties and diagnostic accuracy of the 
A4FTp for the detection of COAG (Chapter 3) 
4. To assess the case-finding performance of structural (iVue Optical 
Coherence Tomography (OCT)) and functional (Frequency Doubling 
Technology Perimeter (FDT); Moorfields Motion Displacement Test (MMDT); 
Ocular Response Analyzer (ORA)) screening tests used alone or in 
combination for the detection of COAG in a cohort of elderly subjects 
recruited from primary care (Chapter 4)  
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5. To extend the analysis of the screening strategy outlined in 4., to determine 
the predictive value of an optimised panel of structural and functional tests 
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Chapter 2.  
Methodology and reporting of diagnostic accuracy studies 




Introduction to diagnostic testing 
Diagnostic testing plays a key role in clinical decision-making, both in the 
identification of previously undiagnosed conditions and in the monitoring of existing 
conditions, including determining the response to therapy. Technological 
developments, particularly over the last two decades, have led to a significant 
increase in medical diagnostics across all specialties, largely driven by demands 
for earlier detection and increased speed and performance of the tests themselves 
(Nema et al 2014). In the effort to detect disease at its earliest clinical stage, 
diagnostic testing can be associated with unintended harms. These include false 
positives, leading to increased patient anxiety and unnecessary investigations. 
Testing can also result in over diagnosis and potentially unnecessary treatments 
(Holman et al 2017). 
 
Diagnostic accuracy studies 
Diagnostic test accuracy studies compare an ‘index test’ to a reference (‘gold’) 
standard, which is usually the best test available for accurately identifying the 
presence or absence of the condition of interest. There are two main types of 
diagnostic accuracy study (Figure 2.1): cross-sectional studies and diagnostic case 
control designs (also known as two-gate designs). 
• In a cross-sectional study design all patients at risk of having the condition 
of interest, undergo the index and the reference test. At the time of inclusion 
in the study, there is clinical uncertainty about their disease status. Such 
studies are also referred to as ‘single-gate’ studies and are considered to 
more likely to provide a representative estimate of diagnostic test accuracy 
(Leeflang et al 2013). 
• In a two-gate (case-control) design, subjects known to have the target 
condition are recruited and compared to healthy controls. Such studies are 
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prone to bias and may lead to an overestimation of test performance, 
particularly if only sections of the spectrum of disease and spectrum of non-
diseased are included. 
The performance of an index test is usually quantified by measures of 
diagnostic accuracy such as sensitivity and specificity, positive and negative 
predictive values, positive and negative likelihood ratios, the area under the 
ROC curve and diagnostic odds ratios (Šimundić 2009). 
 
 
    One-gate design                                        Two-gate design 






























Methodological quality and bias in diagnostic accuracy studies 
Diagnostic accuracy studies allow a clinician to make an informed decision 
regarding the potential utility of a new test. However, the evaluation of diagnostic 
test accuracy studies presents a number of challenges. The quality of a study is 
determined by its experimental design, the methods by which the study participants 
are recruited, the conduct of the index and reference tests and whether interpreters 
of the tests are masked. Overstating or understating results of new tests could lead 
to the premature adoption of a poorly performing test or delayed adoption of a high-
quality test (Azuara-Blanco et al 2012). 
The first Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool was 
created in 2003 (Table 2.1) and provides a useful checklist to assess the 
methodological quality (internal and external validity) of a diagnostic accuracy 
study. QUADAS is used by NICE and has been adopted by the Cochrane 
collaboration for the systematic reviews of diagnostic test accuracy. The tool is 
structured as a list of 14 items which are answered as ‘yes’, ‘no’ or ‘unclear’. The 
items cover the main sources of bias, including: spectrum/sampling bias, 
verification bias, disease progression bias, attrition bias further described in Table 
2.2 as well as items asking about the execution of index and reference tests 




Table 2.1 – QUADAS 2003 items 
1 Was the spectrum of patient’s representative of the patients who will 
receive the test in practice? 
2 Were selection criteria clearly described? 
3 Is the reference standard likely to correctly classify the target condition? 
4 Is the time period between reference standard and index test short 
enough to be reasonably sure that the target condition did not change 
between the two tests? 
5 Did the whole sample or a random selection of the sample, receive 
verification using a reference standard of diagnosis? 
6 Did patients receive the same reference standard regardless of the 
index test result? 
7 Was the reference standard independent of the index test (i.e. the index 
test did not form part of the reference standard)? 
8 Was the execution of the index test described in sufficient detail to permit 
replication of the test? 
9 Was the execution of the reference standard described in sufficient 
detail to permit its replication? 
10 Were the index test results interpreted without knowledge of the results 
of the reference standard? 
11 Were the reference standard results interpreted without knowledge of 
the results of the index test? 
12 Were the same clinical data available when test results were interpreted 
as would be available when the test is used in practice? 
13 Were uninterpretable/ intermediate test results reported? 





Table 2.2 – Sources of bias of diagnostic accuracy studies (adapted from 
Roever et al 2015) 
Source of bias Explanation 
Spectrum bias When included patients do not represent the 
intended spectrum of severity for the target 
condition. 
Classification bias When the reference test does not correctly classify 
patients with the target condition. 
Information bias When the index results are interpreted with 
knowledge of the reference test results, or with more 
(or less) information than in practice 
Verification bias Ideally, all those who are tested with the index test 
should receive verification by the reference test 
(gold standard). 
Failure to do so can cause bias in accuracy 
estimates and is known as verification bias. Partial 
verification bias occurs when a proportion of 
patients do not undergo the reference test. 
Differential verification bias occurs when an 
alternative reference test is used to classify disease.  
Attrition Bias When withdrawals or uninterpretable test results are 
excessive or not adequately explained. 
Disease progression bias When the patients’ condition changes between 
administering the index and reference test 
  
For the original published study (Fidalgo et al 2015) and in the 2019 update 
described in this Chapter, we used the 2003 version of the QUADAS risk of bias 
tool, However, an improved version of the tool (QUADAS-2) has been developed 
(Whiting et al 2011) and is now the current standard for systematic reviews of 
diagnostic test accuracy. One of the major changes in QUADAS-2 is that the first 
three domains (patient selection, index test and reference test) as well as risk of 
bias, are also assessed in terms of concerns regarding applicability. 
 
Quality of reporting of diagnostic accuracy studies 
Reporting guidelines are tools developed to aid accurate, transparent and 
complete reporting of the key aspects of research studies, including a description 
of methods and findings. These guidelines are typically in the form of a checklist. 
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Probably the most commonly used and best-known reporting guideline is the 
CONSORT Statement (CONsolidated Standards Of Reporting Trials), which 
consists of a 25-item checklist of the essential items to include in a randomised 
controlled trial (RCT) report and a flow diagram template. The CONSORT 
statement was first published in 1996 and subsequently revised in 2001 and 2010 
(CONSORT 2010). Since the development of this initial reporting guideline, there 
has been a proliferation of new reporting guidelines to improve the quality of 
published reports for most of the common types of study design. 
The purpose of the STARD statement (Standards for Reporting of Diagnostic 
Accuracy Studies) was to develop a similar checklist to improve the completeness 
and transparency of reporting of studies of diagnostic accuracy (Bossuyt et al 
2003). STARD consists of a list of 25 items covering the main sections of the paper 
and promoted the use of a flow diagram to present the study design and report the 
exact number of patients at each stage of the study (Table 2.3). The development 
of STARD started with an extensive search of several databases (MEDLINE, 
EMBASE, BIOSIS and methodological database from the Cochrane 
Collaboration). Following a review of relevant publications, a comprehensive list of 
items was created. A conference was organised with the aim of reducing the list of 
potential items, and to discuss the optimal format and phrasing of the checklist. A 
version of the checklist was field-tested and placed on a website with a request for 
comments. When all feedback was collected and considered, the STARD 
committee assembled the final version of the checklist and flow chart. STARD was 
disseminated via a series of publications in key journals together with guidance on 
the use of the checklist (Bossuyt et al 2003). The STARD statement was updated 
in 2015 (Bossuyt et al 2015). The update incorporated new information on sources 
of bias and made the checklist easier to use. The STARD 2015 statement 
increased the number of essential reporting items from 25 to 30. The same team 
have also developed a checklist for reporting essential items in journal or 




Table 2.3 - STARD 2003 Checklist 
 TITLE/ ABSTRACT 
1 Identify the article as a study of diagnostic accuracy (recommend 
MeSH heading ‘sensitivity and specificity’). 
 INTRODUCTION 
2 State the research questions or study aims, such as estimating 
diagnostic accuracy or comparing accuracy between tests or across 
participant groups. 
 METHODS 
3 Describe the study population: the inclusion and exclusion criteria, 
setting and locations where the data were collected. 
4 Describe participant recruitment: was recruitment based on 
presenting symptoms, results from previous tests or the fact that the 
participants had received the index tests or the reference standard? 
5 Describe participant sampling: was the study population a 
consecutive series of participants defined by the selection criteria in 
items 3 and 4? If not, specify how participants were further selected. 
6 Describe data collection: was data collection planned before the 
index test and reference standard were performed (prospective 
study) or after (retrospective study)? 
7 Describe the reference standard and its rationale. 
8 Describe technical specifications of material and methods involved 
including how and when measurements were taken, and/or cite 
references for index tests and reference standard. 
9 Describe definition of and rationale for the units, cut-offs and/or 
categories of the results of the index tests and the reference 
standard. 
10 Describe the number, training and expertise of the persons 
executing and reading the index tests and the reference standard. 
11 Describe whether or not the readers of the index tests and reference 
standard were blind (masked) to the results of the other test and 
describe any other clinical information available to the readers. 
12 Describe methods for calculating or comparing measures of 
diagnostic accuracy, and the statistical methods used to quantify 
uncertainty (e.g. 95% confidence intervals) 





14 Report when study was done, including beginning and ending dates 
of recruitment. 
15 Report clinical and demographic characteristics of the study 
population (e.g. age, sex, spectrum of presenting symptoms, co-
morbidity, current treatments, recruitment centres). 
16 Report the number of participants satisfying the criteria for inclusion 
that did or did not undergo the index tests and/or the reference 
standard; describe why participants failed to receive either test (a 
flow diagram is strongly recommended). 
17 Report time interval from the index tests to the reference standard, 
and any treatment administered between. 
18 Report distribution of severity of disease (define criteria) in those 
with the target condition; other diagnoses in participants without the 
target condition. 
19 Report a cross-tabulation of the results of the index tests (including 
indeterminate and missing results) by the results of the reference 
standard; for continuous results, the distribution of the test results 
by the results of the reference standard. 
20 Report any adverse events from performing the index tests or the 
reference standard. 
21 Report estimates of diagnostic accuracy and measures of statistical 
uncertainty (e.g. 95% confidence intervals). 
22 Report how indeterminate results, missing responses and outliers 
of the index tests were handled. 
23 Report estimates of variability of diagnostic accuracy between 
subgroups of participants, readers or centres, if done. 
24 Report estimates of test reproducibility, if done. 
 DISCUSSION 






Diagnostic testing in ophthalmology 
The field of ophthalmology has seen significant developments in diagnostic testing. 
New tests are available that evaluate a variety of structural and functional ocular 
parameters. These allow clinicians to perform a more comprehensive eye 
examination, to assist in ruling in or ruling out a particular disease or providing 
prognostic information in those with established disease. Glaucoma presents a 
particular diagnostic dilemma. Epidemiological studies have shown that 
approximately half of glaucoma is undiagnosed in developed countries (Tielsch et 
al 1991; Klein et al 1992; Mitchell et al 1996; Quigley et al 1997; Weih et al 2001) 
and over 90% in developing countries (Ramakrishnan et al 2003; Vijaya et al 2008; 
Garudadri et all 2010; Budenz et al 2013). Whilst on the one hand it is essential to 
detect glaucoma before it causes visual disability (Johnson et al 2017), at the same 
time its low prevalence in the general population presents a challenge for case-
finding. Even using tests with very high sensitivities and specificities will still result 
in a high proportion of false positives (Lawrenson et al 2014). 
The aim of this study was to assess the methodological quality of diagnostic 
accuracy studies of perimetric tests in glaucoma, using the QUADAS tool and 
evaluate the accuracy and completeness of reporting of these studies based on 
the STARD checklist. We also investigated the possibility of an improvement in the 






We used the OVID platform to search relevant bibliographic databases (MEDLINE, 
EMBASE, and Global Health) to identify diagnostic accuracy studies of perimetry 
published over a 25-year period between January 1993 and October 2019. The 
initial search (reported in Fidalgo et al 2015) was conducted in August 2013 and 
compared two time periods (1993-2003; 2004-2013), before and after publication 
of the original STARD checklist in 2003. An updated search was performed in 
October 2019, covering the period 2013-2019. The search terms used for both 
searches are described in Table 2.4. The search was limited to publications in the 
English language and studies performed on human subjects and included 
synonyms relating to perimetry, glaucoma and diagnostic test accuracy. 
 
Study selection 
For the published review, titles and abstracts from the bibliographic searches were 
screened by a single reviewer (BF) and for the 2019 update by two reviewers (BF 
and JL). Full-text articles were obtained for records judged relevant, or possibly 
relevant, by at least one review author. Reasons for exclusion were documented 
at this stage. Studies were included if they reported on measures of diagnostic 
accuracy of perimetry in glaucoma. 
 
Data extraction and management 
Assessment of methodological quality (QUADAS) and quality of reporting (STARD) 
of included studies 
A data extraction form was prepared for each of the checklists in Microsoft Excel 
to score each item. A written justification for each judgement was included in the 
spreadsheet. 
One reviewer (BF) assessed each of the included studies for methodological 
quality using the original 2003 QUADAS tool (Table 2.1) to assess the susceptibility 
to bias based on published guidance (Whiting 2003). All studies were evaluated, 
and the 14 questions were answered as ‘yes’, ‘no’ or ‘unclear’, corresponding to 
’high’, ’low’ or ’unclear’ risk of bias (lack of information or uncertainty over the 
potential for bias) for each domain.  
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The same reviewer (BF) also assessed each of the included studies for quality of 
reporting using the 25 item STARD 2003 checklist (Table 2.3). The checklist 
includes items that are arranged under the following headings: (1) Title, abstract, 
and keywords (1 item), (2) Introduction (1 item), (3) Methods (11 items), (4) Results 
(11 items), and (5) Discussion (I item). Each item was graded by one reviewer (BF) 
as ‘fully’, ‘partially’, or ‘not reported’ according to predefined criteria (Bossuyt et al 
2003) (Table 2.3). Items that were ‘not applicable’ were recorded as such. For 
example, given that perimetry is a non-invasive test the item ‘Report any adverse 
events from performing the index tests or the reference standard’ was excluded for 
all studies. We also recorded whether each study author cited the STARD checklist 
in the paper. 
Inter-rater reliability 
For the published review, two reviewers (JL and DC) independently rated QUADAS 
and STARD in a 20% random sample of included studies. An inter-rater reliability 
analysis was performed using the weighted Kappa statistic to determine 
consistency among reviewers (Landis & Koch 1977). For the update, BF rated all 
studies and these were then independently checked by JL. In all cases 
disagreements were resolved by consensus. 
Evaluation of ophthalmic journal endorsement of reporting guidelines 
In the originally published review, the ‘Instructions for Authors’ guidance of each of 
the Journals in which the articles were published was checked for references to 
STARD and whether adherence to STARD was a requirement for reporting 
diagnostic test accuracy studies. Following the updated search, this process was 
repeated to incorporate the new studies. For comparison, we also documented 
whether the instructions to authors referenced the CONSORT Statement, which 
describes the minimum set of recommendations for reporting randomized 
controlled trials that was first published in 1996.  
Data synthesis and statistical analysis 
Descriptive statistics were used to present the number and proportion of studies 
scoring ‘yes’ for each QUADAS domain for the periods before and after publication 
of the STARD tool in 2003. The overall adherence to STARD was calculated as 
the mean number and percentage of reported items for each item for the periods 
1993-2003 and 2004-2019. An independent samples t-test was used to analyse 
differences in the percentage of reported STARD and QUADAS items for periods 
before and after publication of the guidelines.  
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Table 2.4. OVID search strategy 
1. Perimetry 
2. Perimeter 
3. Standard Automated Perimetry 
4. SAP 
5. Visual field 
6. Motion displacement test 
7. Frequency doubling technology 
8. Flicker Defined Form 













22. 20 and 21 
23. Diagnostic Accuracy 
24. Diagnostic performance 
25. Precision 
26. ROC 
27. Receiver operating characteristic 
28. Sensitivity and specificity 
29. Sensitivity 
30. Specificity 
31. Diagnostic odds ratio 
32. DOR 
33. Area under the receiver operating characteristic curve 
34. AUC 
35. Likelihood ratio.  
36. or/23-35 
37. 22 and 36 






44. Case finding 
45. or/38-44 




Results of search 
The initial search, conducted in August 2013, identified 488 articles of which, 58 
were eligible for inclusion in the published review (Fidalgo et al 2015). The search 
was updated in October 2019. This yielded 782 articles, 647 articles were excluded 
during title and abstract screening, as they were either duplicates (N=4), not written 
in English (N= 1) or failed to meet the inclusion criteria due to: not glaucoma (N= 
19), not perimetry (N=403), did not report a diagnostic accuracy study (N=92), were 
reviews, conference abstracts, letters or notes or editorials or surveys (N=128). 
One hundred and thirty one articles were selected for full text screening. Following 
the assessment of the full text of the articles, a further 55 were excluded. 76 studies 
were included in the updated analysis covering the period 1993-2019. Figure 2.2 
shows the PRISMA flow diagram. Details of the included studies in terms of the 
index and reference test are provided in Appendix 1. The most commonly used 
reference standard was a combination of optic disc examination, intraocular 
pressure measurement and standard automated perimetry (used in 21% of 
studies) an additional 16% also included gonioscopy. 
 
Inter-rater reliability for QUADAS and STARD  
Assessment of inter-rater reliability using the weighted kappa statistic, showed 
substantial agreement between reviewers. Kappa values for QUADAS and STARD 








































Records identified through 
database searching  
(n = 782) 
Records after duplicates removed  
(n = 778) 
Records screened  
(n = 778) 
Records excluded  




(n = 131) 
Full-text articles 
excluded, with reasons 
(n = 55) 
Not a diagnostic accuracy 
study = 27 
Ocular Hypertension = 2 
Conference paper = 1 
Not Ophthalmology = 2 
Not Perimetry = 3 
Not in English = 1 
Not Glaucoma = 4 
Studies included in 
quantitative analysis  
(n = 76) 
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Compliance with STARD 2003 
Given that perimetry is non-invasive, the STARD item ‘Adverse effects from 
performing index or reference tests’ was judged to be not applicable. The overall 
adherence to STARD based on 24 items was 51.5% (IQR 27.5 to 73.5%). Table 
2.5 presents the adherence to STARD for each item for studies published between 
1993 and 2019. Significant variability in the quality of reporting was observed, with 
the percentage of items being reported ranging from 7-100%. The most 
consistently reported items included: stating the research questions/study aims 
(item 2), description of participant recruitment (item 4), and discussion of the 
clinical applicability of the study findings (item 25). The most inconsistently 
reported items included: a description of whether the readers of the index tests and 
reference standard were masked to the results of the other test (item 11), a 
description of methods for test reproducibility/variability (item 13) and reporting of 
estimates of test reproducibility (item 24). 
Figure 2.3 shows the STARD assessment of each article arranged chronologically 
by year of publication. The median score for articles published before and after the 
development of STARD was similar: 1993-2003, median=11 (range 6 to 15); 2003-
2019 median=13 (range 8 to 22). The percentage of reported items showed no 
overall improvement between the two reporting periods (Figure 2.4) (P = 0.1693). 
Although items relating to the ‘Introduction’ and ‘Discussion’ were consistently 
reported pre and post STARD, (Figures 2.4 and 2.5). The publication of the STARD 
reporting guidelines appear not to have substantially improved in the reporting of 
items pertinent to the methods and results sections (Figure 2.5). Only three of the 



















% N = 22 N = 54 N = 76 
TITLE/ ABSTRACT 
1* Identify the article as a study 
of diagnostic accuracy 
18 (82) 49 (90) 87 8 
INTRODUCTION 
2 State the research questions 







3 The study population 4 (18) 22 (42) 34 24 






5 Participant sampling 16 (73) 36 (63) 66 -10 
6 Data collection strategy 8 (36) 32 (54) 49 18 
7 The reference standard 6 (27) 37 (69) 56 42 
8 Technical specifications of 
material and methods 
13 (59) 46 (83) 76 24 
9 Definition of and rationale of 
the index tests and the 
reference standard 
10 (45) 41 (73) 64 28 
10 The number, training and 
expertise of the persons 
executing and reading the 
tests 
7 (32) 12 (21) 24 -11 
11 Whether or not the tests were 
masked to the readers 
2 (9) 11 (21) 17 12 
12$ Methods for calculating and 
comparing measures of 
diagnostic accuracy and 
uncertainty 
2 (9) 13 (23) 19 14 
13 Methods to calculate 
reproducibility 




14 When the study was done 3 (14) 22 (42) 33 28 
15 Clinical and demographic 
characteristics 
13 (59) 37 (77) 71 18 
16 Participant flow 5 (23) 21 (35) 31 12 
17 Time interval between index 
and reference standard 
3 (14) 14 (23) 20 9 
18 Distribution of severity of 
disease and other diagnoses 
18 (82) 44 (88) 86 6 
19 Cross tabulation of the 
results of the index tests 
12 (55) 36 (65) 61 10 
20 Adverse effects from 
performing index or reference 
tests 
NA NA NA NA 
21$ Estimates of diagnostic 
accuracy and measures of 
uncertainty 
3 (14) 24 (44) 34 30 
22 How indeterminate results, 
missing responses and 
outliers of the index tests 
were handled 
6 (27) 20 (38) 34 11 
23** Estimates of diagnostic 
accuracy between subgroups 
11 (50) 29 (58) 56 8 
24 Estimates of test 
reproducibility 
2 (9) 6 (10) 10 1 
DISCUSSION 
25 Discuss the clinical 








NA - not applicable, due to the non-invasive nature of the test. 
* Considered to be positive if the words diagnostic accuracy appeared in the 
title or abstract, or if the article was identified using the MeSH term sensitivity 
and specificity. 
** Considered to be NA if there were no subgroups.  
$ If only estimates of diagnostic accuracy without a measure of uncertainty 




   

























Figure 2.4 – STARD items 100% stacked bar before and after introduction of STARD in 
2003 
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Figure 2.5. Bar chart showing the STARD items by Domain before and after 2003 
 
Methodological Quality Assessment of Included Studies 
The overall median number of QUADAS items scored as ‘Yes’ for articles 
published between 1993 and 2019 (N=76), was 9 (range 2 to 14). The median 
score for articles published before and after the development of STARD was 
similar: 1993-2003, median=8 (range 2 to 13); 2003-2019 median= 9 (range 4 to 
14). Table 2.6 summarises the results for each item for each time-period and 
Figure 2.6 shows the QUADAS assessment of each article arranged 
chronologically by year of publication and in Figure 2.7 grouped items into risk of 
bias domains. The percentage of reported items showed no overall improvement 
between the two reporting periods (P = 0.1234), although specific items relating to 
the reference test and the flow and timing of the study showed a modest 


























































1 Was the spectrum of patients 
representative of the patients who will 











3 Is the reference standard likely to correctly 






4 Is the time period between reference 
standard and index test short enough to be 
reasonably sure that the target condition 
did not change between the two tests? 
2 (9) 24 
(50) 
40 41 
5 Did the whole sample or a random 
selection of the sample, receive verification 






6 Did patients receive the same reference 







7 Was the reference standard independent of 
the index test (i.e. the index test did not 






8 Was the execution of the index test 
described in sufficient detail to permit 






9 Was the execution of the reference 
standard described in sufficient detail to 






10  Were the index test results interpreted 







11 Were the reference standard results 
interpreted without knowledge of the results 






12 Were the same clinical data available when 
test results were interpreted as would be 














































Figure 2.7 – QUADAS items before and after introduction of STARD 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%100%
14 - Withdrawals explained?
13 - Uninterpretabe results reported?
12 - Relevant clinical data available?
5 - Partial verification bias avoid?
4 - Acceptable delay between tests?
10 - Index test results masked?
8 - Index test description appropriate?
11 - Reference standard results masked?
9 - Reference test description appropriate?
7 - Incorporation bias avoid?
6 - Differential verification bias avoid?
3 - Acceptable reference standard?
2 - Selection criteria clearly described?
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Figure 2.8. Bar chart showing the percentage of QUADAS items scored as yes ordered 
by Domain before and after 2003 
 
Evaluation of journal endorsement of reporting guidelines 
The included papers were published in 18 different journals. We were unable to 
access instructions for authors for two of the included journals: Bulletin de la 
Societe Belge d’Ophthalmologie and the African Journal of Medicine and Medical 
Sciences. Only 3 (19%) of these journals recommended that authors should use 
the STARD checklist and flow diagram for reports of diagnostic test accuracy. By 
comparison, 56% of journals stipulated that authors should use CONSORT when 















































Table 2.7. Results of audit of STARD and CONSORT inclusion in journal 
instructions to authors. 
JOURNAL  STARD CONSORT 
Eye  N Y 
Investigative Ophthalmology & Visual Science  N N 
Acta Opthalmologica N N 
British Journal of Ophthalmology  Y Y 
Japanese Journal of Ophthalmology  N N 
American Journal of Ophthalmology N Y 
Journal of Glaucoma  N N 
Archives of Ophthalmology (now JAMA Ophthalmol)  Y Y 
Singapore Medical Journal  N N 
Ophthalmology  N Y 
Graefe's Archive for Clinical and Experimental 
Ophthalmology  N N 
European Journal of Ophthalmology  Y Y 
Ophthalmic Epidemiology N Y 
Optometry and Vision Science N Y 
Clinical and Experimental Ophthalmology N N 







The aim of this study was to assess the quality of reporting and overall 
methodological quality of diagnostic accuracy studies that used perimetry to detect 
functional vision loss in glaucoma. We further investigated the impact of the 
publication of STARD on the quality of reporting by comparing articles published 
before and after the development and dissemination of the STARD checklist in 
2003. The initial search and analysis was carried out in 2013, covering the period 
1993-2013. This allowed a comparison of published studies over two 10-year time 
periods pre- and post STARD. We used the QUADAS tool to assess 
methodological quality and hypothesised that any improvements in reporting of 
diagnostic test accuracy studies would potentially lead to a corresponding 
improvement in overall methodological quality. The results of the initial analysis 
(1993-2013) were published in 2015 (Fidalgo et al 2015). In the same year, a 
revised 30-item STARD checklist was published (Bossuyt et al 2015). We 
subsequently updated the review in October 2019 to include studies that had been 
published since 2013. This identified a further 18 studies. 
Across the whole of the evaluation period, the overall compliance with STARD was 
poor, with only 50% of the items adequately reported. A comparison of the studies 
published before and after the development of the of the original STARD checklist 
in 2003 found that overall, reporting had not substantially improved, with no further 
significant improvement since the publication of the updated checklist in 2015. 
Significantly, only three of the included studies reported that they had used the 
STARD checklist in the development of their manuscript. This is possibly not 
surprising since less than 20% of the included journals recommended in their 
submission instructions that authors should use STARD when reporting diagnostic 
test accuracy studies. By contrast, approximately 50% of the same journals 
referenced CONSORT for reporting RCT’s. Our results, showing poor adherence 
to the original STARD checklist were consistent with previous studies in 
ophthalmology (Siddiqui et al 2005; Shunmugem et al 2006; Johnson et al 2007; 
Paranjothy et al 2007; Zafar et al 2008; Castillo et al 2014) and in other medical 
specialities (Coppus et al 2006; Wilczynsky et al 2008).  
Given the poor reporting of the included studies, it is possibly not surprising that 
there was no statistical overall improvement in methodological quality (as judged 
by QUADAS on published studies before and after 2003). Intuitively, we would 
expect that even a well-conducted study would score poorly on a quality 
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assessment tool if the methods and results were not reported in sufficient detail. 
However, a recent study (Michelessi et al 2017) examined the relationship between 
STARD and QUADAS in a large set of studies on glaucoma. The authors reported 
that the relationship between the two tools was partial and difficult to interpret. 
Furthermore, they suggested that raters were using substantial context-specific 
knowledge when conducting a QUADAS assessment. 
In the updated analysis, we examined QUADAS items grouped into four risk of bias 
domains. This analysis revealed a small to moderate improvement in some 
domains with the largest improvement in the timing and flow domain. This domain 
includes items relating to withdrawals and uninterpretable test results, evaluating 
partial verification bias and inappropriate delays between performing index and 
reference tests.  
Over the past 20 years, reporting guidelines have been developed for a variety of 
study designs to assist health researchers in writing up their work for publication. 
These guidelines specifying a minimum set of items that are required to provide a 
transparent account of what was done together with a clear description of the 
results of the study. The Enhancing the Quality and Transparency of Reporting 
(EQUATOR) Network is an international organisation that aims to improve the 
quality of reporting of health research (Equator Network 2018). One of the goals of 
the organisation is to promote the use of reporting guidelines and support journals 
in implementing them. The Network maintains an online library of reporting 
guidelines for the main study types. There is an accumulating body of evidence to 
suggest that Journal endorsement of CONSORT improves the reporting of RCTs, 
although reporting is still sub-optimal (Turner et al 2012). Although it is unclear 
whether the poor adoption of STARD by ophthalmology journals is the primary 
reason for the incomplete reporting of diagnostic accuracy studies identified in this 
and other studies in ophthalmology. However, the experience from CONSORT 
would suggest that the implementation of STARD and enforcement by journal 
editors is likely to lead to quality improvements in the reporting of these studies. 
Strengths and limitations of this study 
This study used systematic methods to evaluate methodological quality and 
standards of reporting of diagnostic accuracy studies that were published in a 
defined area of ophthalmology. Our findings have added to the body of literature 
highlighting poor methodological quality and poor reporting of diagnostic accuracy 
studies across many health specialities. Despite the availability of STARD 
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reporting standards, there is clear evidence that these are not being followed. It is 
possible that the same advocacy strategies that were successful in increasing the 
adoption of the CONSORT guidelines for the reporting of RCTs could be applied 
to STARD. Much of the responsibility lies with journal editors, who should insist 
that STARD reporting guidelines are followed by requiring a completed checklist to 
be included with each paper submission. 
We acknowledge a number of methodological limitations of the current study 
including:  
1. Only assessing articles published in English 
2. Using a single reviewer to screen all titles and abstracts and 80% of the 
QUADAS and STARD ratings.  
Since the starting work on the review, updated STARD guidance has been 
produced (Bossuyt et al 2015). However, given that we were comparing studies 
published following the development of STARD in 2003, this early version was 
used throughout. Similarly, QUADAS has also been updated (Whiting 2011) and 
this version has now been adopted by organisations such as NICE and the 
Cochrane collaboration. However, at the point that we began the study, QUADAS 





2.5. Role in the study 
Under the supervision of Professors Lawrenson and Crabb, I wrote the protocol for 
the systematic review, conducted the bibliographic searches, screened the titles 
and abstracts for potentially included studies, extracted data and conducted the 
STARD and QUADAS assessments. I also wrote the first draft of the manuscript 
that was published in Ophthalmic and Physiological Optics. For the updated review 
described in this Chapter, I repeated the searches, extracted and analysed the 
data from the newly included studies. 
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Chapter 3.  
Development of a new glaucoma screening test using 
temporally modulated flicker 
 
3.1 Introduction 
Glaucoma is a leading cause of visual morbidity, accounting for 6.6% of blindness 
globally (Bourne et al 2013). As the disease is typically asymptomatic in its early 
stages, many patients already have significant functional visual loss at the time of 
diagnosis. Although the disease fulfils many of the Wilson-Jungner criteria (Wilson 
et al 1968) to justify the development of a screening programme, screening of the 
general population for glaucoma has not been found to be cost-effective in any 
country (Hernandez et al 2008), although there is the potential for targeted 
screening of high-risk groups (e.g. those of African ancestry or with a family history 
of glaucoma) (Burr et al 2007). As an alternative to the current practice of 
opportunistic screening (case-finding) for chronic open angle glaucoma (COAG) 
(Figure 3.1A), a pathway has been proposed that could potentially improve cost-
effectiveness by performing an initial  technology-based assessment to determine 
the probability of disease and then referring those who require a more detailed 
ophthalmic assessment (Figure 3.1B) (Burr et al 2007).  
 
Figure 3.1. – A). Current opportunistic screening pathway for COAG. B). Alternative 
pathway incorporating a technology-based triage assessment. To be consistent with NICE 
guidance, specialist evaluation for the definitive diagnosis of COAG is required by a 
consultant ophthalmologist based on gonioscopy, threshold central automated perimetry, 




A systematic review evaluating screening tests for detecting COAG concluded that 
no test or group of tests is clearly superior for glaucoma screening (Mowatt et al 
2008). As well as being able to accurately distinguish normal individuals from those 
who have the disease, an effective screening test for glaucoma should ideally be 
easy to administer and interpret, portable, quick, and be acceptable to the people 
being tested. Historically, the reference standard for assessing visual function in 
glaucoma has been standard automated perimetry (SAP). However, SAP has a 
number of shortcomings: the test is time consuming, it lacks portability, and the 
technique is associated with high intra-participant variability (Spry et al 2001). 
Given the limitations of SAP, several studies have investigated the value of 
alternative psychophysical tests (McKendrick et al 2005).  
Reduced sensitivity to temporally modulated sinusoidal flicker has been shown to 
provide an indicator of compromised retinal ganglion cell function, suggesting that 
assessment of flicker sensitivity could be a potentially useful method for detecting 
glaucomatous damage (Tyler et al 1981; Lachenmayr et al 1992; Horn et al 1997). 
Contrast modulation flicker uses a stimulus that is matched in luminance to the 
background. The contrast of the stimulus is then modulated temporally according 
to a fixed frequency, and the amplitude of flicker modulation needed for detection 
of the stimulus is determined (Tyler et al 1991). When presenting this stimulus, it 
is important to avoid sudden stimulus onsets and offsets that can disrupt the ability 
to detect the flicker at a particular frequency. To prevent this, flicker modulation 






Figure 3.2. – Flicker modulation stimulus within cosine envelope 
 
The aim of the present study was to develop a new psychophysical algorithm to 
determine flicker sensitivity thresholds in susceptible areas of the visual field that 
could be used as a rapid screening test for COAG. Given the low prevalence of the 
disease in the general population, a large proportion of those screened would be 
expected to be normal or close to normal, therefore it is important to initially assess 
the performance of the algorithm in a disease-free population, to determine how 
efficiently they could be screened and gain an initial estimate of the stability, test-
retest reliability, speed and physiological variation in flicker sensitivity in the normal 




3.2. Materials and methods 
This study was approved by the School of Health Sciences Research Ethics 
Committee, City, University of London and conducted according to the tenets of 
Declaration of Helsinki. Written informed consent was obtained from all 
participants.  
 
Development of the Accelerator 4 alternative forced choice flicker test 
prototype 
Stimulus Design 
Previous research has suggested that with comparatively few perimetric stimuli, it 
is possible to achieve high sensitivity for glaucoma detection (Henson et al 1988; 
Krakau et al 1989; De la Rosa et al 1990; Sugimoto et al 1998), which reflects the 
strong inter-point correlations within regions of the visual field that are adversely 
affected in glaucoma. The Accelerator 4 alternative forced choice flicker test 
prototype (A4FTp) was designed to combine this approach with the efficiency of a 
four-alternative forced-choice strategy for psychophysical testing. The test involves 
the participant undertaking a series of trials to detect a target stimulus from four 
possible stimulus locations (Figure 3.3). The selection of stimulus locations for this 
first iteration of the A4FTp was based on the research by Wang and Henson (Wang 
et al 2013), who used optimized sub-sets of the conventional 24-2 test pattern 
based on the positive predictive value (PPV) of each test location to identify 
glaucomatous visual field loss (Nicholas et al 1980; Keltner et al 2003). The A4FTp 
uses two 11° diameter circular stimuli located in the temporal superior and inferior 
arcuate regions of the visual field 9–21° from fixation (Figure 3.3), with the other 
two equivalently sized stimuli spanning the horizontal meridian (14–26° from 
fixation), corresponding to the location of the ‘nasal step’ that is often seen in 
COAG. The configuration was mirror reversed for testing the left eye. 
The target stimulus was a 0.75 s period of 30 Hz sinusoidal flicker ramped on and 
off according to a raised cosine envelope in order to avoid onset and offset 
transients, presented at a viewing distance of 33 cm on a high refresh rate screen 
(120 Hz) in a uniform red field (610 nm) with a mean background luminance of 19 
cd m-2. The presentation with long-wavelength light was designed to minimise 
transmission losses in the optic media.  
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To ensure that the luminance of the stimulus is matched to the luminance of the 
background, the display gamma, a function that controls overall brightness of an 
image, was linearized to within 0.5% of the maximum intensity to avoid any change 





B      C 
Figure 3.3. A. Right-eye spatial arrangement for the A4FTp test stimuli presented in a red 
field on a high refresh rate screen. The mirror image configuration was used for left-eye 
viewing. B. Spatial location of the A4FTP flicker test locations for the right eye compared 
to the HFA 24-2 pattern. C. Field map by Wang and Henson (Wang et al, 2013). The 
configuration was mirror reversed for testing the left eye. (UN – Upper Nasal, LN – Lower 






The glaucoma screening algorithm uses a rapid four-alternative forced-choice 
staircase paradigm that we term the ‘Accelerator method’ to measure threshold 
sensitivity for 30 Hz sinusoidal flicker simultaneously in four peripheral field regions 
by means of a novel staircase termination criterion, such that the one-up/two-down 
staircase in log modulation steps of 1 dL terminates when the standard deviation 
of the last n trials becomes less than 1 step. Unlike conventional staircases, this 
straightforward algorithm ensures that the staircase reaches a stable asymptotic 
performance level of low variability before terminating.  
The performance of the staircase depends on the value chosen for n, and the steps 
should be defined in a domain where the variance is uniform. Since most 
psychophysical performance operates in domains where the variance is 
proportional to signal strength (Weber’s Law), it is generally best to run the 
staircase in logarithmic steps.  Since, it is helpful to have a definitive change in the 
stimulus on each trial, steps of 1 dL (0.1 log10 units) are an effective choice for the 
step size. 
The algorithm was implemented using a Dell computer (Inter core 2 Duo CPU 
E7500 @2.93 GHz and 4 GB RAM), displayed on a 144 Hz Asus VG248QE 24-
inch 3D LED monitor running at 120 Hz, and used an Accmat™ USB wired 19 key 
number numeric keypad as the test input device. The computer was running on a 
64 - Bit Windows 7 Enterprise, Service pack 1, MATLAB R2014a and Psychtoolbox 
version 3.0.11. 





Algorithm performance simulation 
To illustrate the performance of the A4FTp staircase method, simulations of its 
performance were run using Gaussian noise with a standard deviation (sigma) of 
0.5, 1 or 2 steps of the staircase, with 100 runs under each condition (Figure 3.4).  
 
 
Figure 3.4. Simulation of the performance of the Accelerator staircase method at three 
levels of step size relative to the noise sigma controlling threshold level (0.5, 1 and 2 
decilogs top to bottom row respectively). Column 1: Overlays of average run length (red 
curves) and threshold estimate (blue curves)  1 standard error of the mean (SEM) (green 
curves) as a function of the criterion cumulation length for the last n values for the sigma 
estimate. Dashed line is the simulated threshold level. Inset gives the average run length 
for a criterion cumulation length of 8 steps. Column 2: Histograms of the corrected threshold 
estimates on each trial simulation. Column 3: Standard deviation (SD) of the threshold 
estimates as a function of run length. Simulation provided by Christopher Tyler. 
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The left column shows the average threshold estimates (blue curves)  1 standard 
error of the mean (SEM, green curves) as a function of number of trials cumulated 
(n). The average is almost independent of the n. It also plots the average run length 
as a function of the criterion run length (red curves). As expected, the average run 
length increases with n, but it can be seen to do so more steeply when the step 
size is small relative to the experimental noise sigma than when it is large (from 
upper left to lower left). For small n, however, the run length remains independent 
of step size, while standard deviation (SD) decreases with step size, so a larger 
step size is to be preferred. Standard deviation decreases with run length 
substantially up to about run lengths of 20 (termination criteria of about 14), to 
about 0.2 sigma for a step size of 2 and about 0.3 sigma for a step size of 1, again 
favouring the larger step sizes.  
The other feature of the average threshold estimates (blue curves in the left column 
of Figure 3,3) is that they lie consistently above the simulated threshold level by an 
amount that is almost invariant with n but is inversely related to step size. The 
resultant threshold estimates (other columns) were therefore corrected for the 
overestimation of the raw threshold levels RAW seen in the left column according 
to the empirical formula:  
CORRECTED = -a . RAW  / k,   where a = 1 dL. 
The middle column shows histograms of the corrected threshold estimates 
resulting from 100 simulations for each of the three step sizes, k.  Note that the 
histograms have a narrow spread, decreasing with step size, and that the peak of 
the corrected estimates is close to the defined threshold level of 10. 
The right column shows the average simulated SD as a function of run length for 
the three step sizes, asymptoting to much less than 1 dL in all cases. Note that 
there is little advantage for run lengths longer than 14. 
The data obtained with the simulation allowed us to select the 8 step (T8) and 12 






A convenience sample of normal participants was recruited from City, University of 
London staff and students. To be eligible for the study, participants were required 
to be 18 years or older with a normal appearance of the optic disc and fundus and 
no known family history of glaucoma in first-degree relatives. All volunteers 
underwent a detailed ophthalmic examination, including SAP (HFA 24-2 SITA 
Standard), to exclude glaucoma or any other ocular diseases that would affect 
flicker sensitivity. Participants were excluded if they had an intraocular pressure 
(IOP) greater than 21 mm Hg in either eye, suspicious appearance of the optic disc 
(rim loss, optic disc haemorrhage, etc.), history of ocular disease, surgery or 
trauma, history of a cerebrovascular event, or diabetes mellitus. None of the 
participants had previous experience of flicker perimetry. 
Selection of suitable threshold criteria  
An initial study was carried out to determine the optimal threshold termination 
criteria (by comparing the performance of the T8 and T12 run lengths) and to 
assess any learning effects that could potentially influence the percentage 
modulation levels. For 20 healthy adults, one eye selected at random underwent 
testing with the flicker test four times on separate occasions during a period of two 
weeks for each criterion run length.  
Participants were given an identical set of instructions on how to perform the test. 
These consisted of: 
• Explaining the general layout of the screen and the number, position and 
timings of the stimuli 
• Familiarising the participant with the numeric keypad and the relationship 
between the keys and stimulus location on the screen 
• Explaining the need to fixate centrally and to select the key on the keypad 
corresponding to the location of each presented stimulus immediately after 
the auditory signal 
•  To press any key if unsure of the stimulus location or if no stimulus was 
seen 
Participants wore near reading prescription if needed, and the eye not being tested 




The starting level was set at 15 dL, which for healthy individuals, is halfway 
between the threshold of about 10 dL and the maximum modulation level of 20 dL. 
For each session, the overall mean modulation level was determined for the four 
test locations and the time taken to conduct the test was recorded. Inter-session 
variations were assessed using the Friedman Test and test-retest coefficients of 
repeatability for the flicker modulation levels were calculated. 
In order to evaluate the inherent variability of the test for each participant, the inter-
participant variability was isolated from the intra-participant variability by 
calculating the mean modulation level across participants for each test location and 
each threshold criterion and then normalizing the individual values to this group 
mean to determine the within-participant variability. 
 
Assessment of individual reliability and learning effects 
To study individual reliability, we evaluated the test-retest repeatability of the flicker 
algorithm. First, we selected 4 volunteers to assess the individual reliability and 
any tendency to improve by learning by taking the test 10 times over a period of 3 
months. Learning effects were assessed by comparing the results of test duration 
and modulation levels of the first session with those of the other four sessions using 
either Friedman’s test or Wilcoxon’s test as appropriate. The intra-participant test–
retest coefficients of repeatability (CoR) were also calculated for the flicker 
modulation levels. All data and statistical analyses were performed using Excel 






Determination of optimal threshold criteria 
Twenty normal participants meeting our inclusion criteria were included in the 
study. Seventy per cent were male, mean age 33.8 years (SD 8.5), mean spherical 
refractive error -0.50 ±2.41D. The analysis was based on 10 right eyes and 10 left 
eyes. 
Table 3.1 shows the average inter-session results for each threshold criterion (T8 
vs T12). A non-parametric Friedman test for the modulation levels rendered a Chi-
square of 6.00, p = 0.111 for the shorter termination criterion (T8) and a Chi-square 
of 5.99, p = 0.112 for the longer termination criterion (T12). The Friedman test for 
run duration rendered a Chi-square of 3.214, p = 0.36 for the shorter T8 termination 
criterion and 17.82, p < 0.001 for the longer T12 criterion. Moreover, for this larger 
sample the mean durations were nearly twice as long for the T12 than the T8 
criterion. 
Table 3.1. Inter-session modulation levels and test durations (per eye) 

























81 ± 22 71 ± 9 76 ± 15 73 ±13 0.36 
Duration (T12) 
(s)  
166 ± 49 148 ± 40 148 ± 40 126 ± 31 < 0.001 
 
Figure 3.5 shows the modulation sensitivity levels and 95% confidence intervals in 









Figure 3.6. Test duration (Dur) per eye in seconds ± 1SD across all 4 sessions for each 





























































We can ask whether the threshold values improved over the four test sessions for 
each participant. The trend is not significant at T8 (p = 0.25) but there was a 
significant decrease in average trial duration for T12 (p < 0.01). This result 
suggests that, in addition to the longer time to reach the criterion at T12, the 
participants had difficulty managing the stability of their responses for this criterion, 
while reaching stable performance within the first run for the T12 criterion. 
Inherent Variability 
To assess the inherent variability of the test for a typical participant, the inter-
participant variability needs to be isolated from the intra-participant variability. The 
global mean sensitivity was thus calculated across participants for each location 
and each threshold criterion and the individual participant values were then 
normalised to this group mean for calculation of the within-participant error terms. 
This procedure removes the across-subject variability without affecting the group 
mean values. 
The results of this analysis are shown in Figure 3.7. There was no significant 
difference in sensitivity among the four chosen field locations for the group of 20 
participants, with either the T8 or T12 criterion. The average within-participant 
standard deviation across the four locations was 0.52 dL for T8 and 1.32 dL for 
T12 (thus giving 95% confidence intervals of 1.01 dL for T8 and 2.59 dL for T12). 
The corresponding values for the Bland-Altman Coefficient of Repeatability are 
1.44 dL and 3.65 dL). The T8 criterion therefore provides a significant advantage 
over the T12, even though the T12 was hypothesised to provide a lower variability 





Figure 3.7. Decilog modulation (Mod) levels 1SD over the four visual field locations, 
normalised to the group mean, for each threshold criterion. These error bars thus represent 
the average individual variability at the four visual field locations. (UN – Upper Nasal, LN – 
Lower Nasal, UT- Upper Temporal and LT – Lower Temporal) 
 
Assessment of individual reliability and learning effects 
To study individual reliability, we evaluated the test-retest repeatability of the flicker 
algorithm. The test was repeated 10 times in four normal observers, shown in 
Figure 3.8 as the average thresholds across the four locations for each observer. 
The goal was to test the stability of the algorithm under optimal conditions rather 







































Figure 3.8.  Trend analysis over 10 runs of the thresholds for each field location averaged 
for four control observers. A:  Data for the criterion run length of 8 (T8 condition). B: Data 
for the criterion run length of 12 (T12 condition). None of the slopes differed significantly 


















































The four control observers completed 10 runs over a four-month period to 
determine stability of the estimates. The average threshold values for the T8 and 
T12 are plotted in Figures. 3.8 A and B. For the T8 condition, all four slopes are 
less than 0.5 dL over the 10 runs, with small differences in the average sensitivity 
across observers and an average   of 1.66 dL.  
For the T12 condition, the data are generally more variable, with an average   of 
1.75 dL and somewhat lower threshold values, but there are again no significant 
trends for improvement with practice.   
The test durations were significantly longer for T12 (mean 147 ± 40 s) compared 
to T8 (Mean 76  15 s) p=<0.0001, indicating a clear advantage of the T8 condition 
in terms of testing efficiency. The total number of responses in the T8 condition 
averaged 42, implying that the stable threshold values were obtained in just over 
10 responses per visual field location. The corresponding number for the T12 
condition was 76. Thus, both in terms of time taken and of variability of the 
threshold estimate, there is a clear advantage for the T8 condition. 
 
3.4. Commentary on the pre-clinical development of the A4FTp 
As part of the pre-clinical development of the A4FTp we evaluated the 
psychometric properties of the test in 20 short-term and 4 long-term participants. 
These datasets both show that there was a significant increase in the time taken 
to reach the 12-point (T12) staircase criterion relative to the 8-point (T8) criterion. 
The average time for T8 was a little over one minute per eye for estimation of the 
four thresholds, while that for T12 was well over two minutes. There was also a 
significant learning effect on completion time for T12 (ranging from 166 s for the 
first session to 126 s for the fourth session) but not for T8. Thus the 8-point 
termination criterion has a clear advantage in terms of both efficiency of the A4FTp 
staircase method in achieving the threshold estimates and stability of its 
performance, with the absence of any learning effect for T8. The question is 
whether this speed advantage was obtained at the cost of a reduction in the quality 
of the resulting threshold estimates.  
There are two relevant measures of the quality of the estimates, stability over time 
and variation across individuals. Within-test variability is caused by several 
aspects, neural noise, decision criteria, and thresholding strategy (Johnson et al 
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1988; Gonzalez de la Rosa et al 2006). Between-test variability has been attributed 
to ocular and neural sensitivity fluctuations (Spry et al 2002). The variability that 
occurs during test and retest is quantified by the degree of scatter between 
measurements taken at different test sessions (Chauhan et al 1999; Spry et al 
2000; Spry et al 2002). Considering firstly the stability over time, we see that there 
was no significant drift in the estimated values for either criterion, for either the 
short- or long-term test series (even though the duration for T12 did significantly 
decrease over time). Thus, the A4FTp staircase was equally stable under all test 
conditions. However, there was a big difference between the criteria in the variation 
between individuals, which had the remarkably low standard deviation of 0.52 dL 
for T8 compared with 1.32 dL for T12. These values may be compared with the 
standard deviation values of ~1.7 dL reported for the population variation of two 
alternative forced choice flicker threshold estimates in previous studies (Tyler et al 
1991). Thus, while the standard deviation for the 12-point criterion is close to the 
range recorded in previous studies, the 8-point criterion markedly reduces the 
standard deviation to about one third of this level implying that the physiological 
strain of the longer runs overcame the statistical advantage of the increased 
number of samples.  
Since variance is defined as the square of the standard deviation, this result further 
implies that about 90% of the variance in the 12-point criterion staircase, was due 
to methodological variations, with no more than 10% of the variance attributable to 
inherent population variability. Moreover, there is no significant gain in reliability for 
the extra time spent to reach the 12-point criterion, and, though slightly lower on 
average, the threshold values themselves are not significantly different from those 
for the 8-point criterion. Thus, we have to conclude from the 20-participant results 
that, of the two approaches evaluated, the 8-point criterion staircase is a more 
effective approach to flicker threshold measurement, with no evident 
disadvantages and a clear time advantage over the 12-point criterion staircase. 
Learning and fatigue effects are an important issue in many psychophysical tests 
and consist of an improvement or degradation, in performance respectively, as a 
function of the duration of the test. The learning effect occurs as the patient 
becomes increasingly familiar with the requirements of the perimetric task and 
manifests as an improvement in sensitivity and a decrease in measurement 
variability over time. This phenomenon tends to increase the false-positive rates 
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for inexperienced examinees, influencing the specificity, and can therefore be 
detrimental to the implementation of any technology used as a screening device. 
Previous findings suggest that learning effects for Frequency Doubling Technology 
(FDT) are mild, regardless of the version of the device used or the screening 
strategy (Lester et al 2000; Khong et al 2001; Spry et al 2001; Fujimoto et al 2002; 
Horani et al 2002; Joson et al 2002; Matsuo et al 2002; Brush et al 2004; Hong et 
al 2007; Centofanti et al 2008). Learning effects are well known for SAP, in that 
subsequent examinations give increased absolute mean sensitivity over the initial 
session (Werner et al 1990; Heijl et al 1996; Schimiti et al 2002). Such learning 
effects were also identified in SWAP (Wild et al 1996; Rossetti et al 2006), and 
flicker perimetry (Bernardi et al 2007). It is impressive, therefore, that the A4FTp 
shows no learning effects in the present control sample, even up to 10 test repeats.   
Testing times of the A4FTp (mean 76 ± 15s for T8 per eye) were faster than other 
glaucoma screening tests that use a threshold strategy, which range from 2.5 to 9 
minutes per eye (Burr et al 2007). Most perimeters used for screening resort to a 
supra-threshold algorithm that sacrifices sensitivity for speed (Burr et al 2007). 
In conclusion, this initial study showed that the T8 version of the A4FTp flicker 
sensitivity test has a shorter duration than equivalent threshold perimeters, did not 





3.5. Diagnostic accuracy of the A4FTp for the detection of COAG 
Purpose 
The diagnostic accuracy of the A4FTp flicker test was determined using a case-
control design were patients with an established diagnosis of COAG were 
compared with those of a control group. The A4FTp Test was also compared with 
two other tests for glaucoma case finding: The Frequency Doubling Technology 
(FDT) perimeter and the iVue Spectral Domain Optical Coherence Tomography 
(SD-OCT). User acceptability data was collected for all screening tests. The study 
was designed and reported, in accordance with the Standards for Reporting of 
Diagnostic Accuracy guidelines (STARD) (Bossuyt et al 2003). 
 
Methods 
Forty consecutive adults with a clinical diagnosis of COAG where recruited using 
the university eye clinic request and also via an advertisement in the International 
Glaucoma Association newsletter. The control group consisted of consecutive non-
glaucomatous adults that were recruited from local optometry practices and the 
university eye clinic. Figure 3.9 shows the flow of patients through the study. 






All participants underwent a reference standard ophthalmic examination on the 
same day as the index tests by an experienced glaucoma-specialist optometrist AJ 
(with training and accreditation within glaucoma clinics in the UK Hospital Eye 
Service), masked to the index tests results. The reference examination included 
Log MAR best correct visual acuity, refraction, IOP using a Goldmann Applanation 
Tonometer (GAT), slit-lamp biomicroscopy, grading of the crystalline lens using 
LOCS II, van Herick assessment of limbal anterior chamber depth (van Herick et 
al 1969), potentially occludable angles examined using gonioscopy, and dilated 
fundus examination with detailed disc assessment using indirect ophthalmoscopy. 
Visual fields were assessed using a Carl Zeiss Humphrey Field Analyzer (HFA) 
with the Swedish Interactive Thresholding Algorithm 24-2 standard pattern (SITA 
Standard). HFA field-testing was repeated for false positives >15%, false negatives 
or fixation losses >33%. 
Inclusion and exclusion criteria 
Adults aged 40 and above were included in the study, control participants included 
in the study where free from ocular disease with normal appearance of the optic 
disc, normal fundus, IOP ≤21 mmHg, and full visual fields. COAG diagnosis was 
based on the following criteria: open anterior chamber angles; presence of 
glaucomatous optic neuropathy (localised absence of neuroretinal rim, cup-to-disc 
ratio 0.7, or interocular asymmetry in vertical cup-to-disc ratio 0.2 in similar sized 
discs); the presence of a concordant glaucomatous field defect using the 24-2 SITA 
algorithm on the HFA. Glaucomatous visual field loss was classified using Hodapp-
Parrish Anderson criteria as early, moderate or advanced (Hodapp et al 1993). 
Participants were excluded if they had a history of angle closure, significant 
diabetic retinopathy, retinal vascular occlusions, peripheral retinal abnormalities, 
optic atrophy, clinically significant cataract [Lens Opacity Classification System III 
(LOCIII)] (Chylack et al 1993), or a neurological field defect. 
Index tests 
All participants underwent testing with all three index tests, A4FTp, FDT (using the 
C20-5 programme), and iVue OCT (RNFL and total retinal thickness), performed 
in a random order by BF who was unaware of the participants’ ocular status. 
Thresholds of abnormality for the index tests were based on cut-offs commonly 





Index and reference tests were performed on both eyes. However, for the purpose 
of the analysis, data from one eye was used. In the case of participants with 
glaucoma, this was the eye with the greater visual field loss (given that the design 
of the A4FTp was optimised to detect more established field loss). For consistency, 
the right eye was selected for the controls; if the right eye was not eligible, the left 
eye was used. 
 
T-tests were used to compare differences between groups to evaluate diagnostic 
test accuracy, Receiver Operator Characteristics (ROC) curves were plotted. 
Differences in the area under the ROC curve (AUROC) for each test parameter at 
the 95% confidence interval (CI) were compared statistically using the DeLong 
method (DeLong et al 1988). Sensitivity, specificity, positive and negative 
likelihood ratios were also calculated. 
 
Results 
Of the 81 invited participants in the study 3 where excluded from the analysis; two 
control participants one with uninterpretable test results on all visual function tests 
and another was identified as a COAG suspect, one COAG participant had bilateral 
neurological visual field defects. Table 3.2 provides a summary of the demographic 
and clinical data for the controls and COAG participants. Statistical differences 




Table 3.2. Demographical and summary clinical data 
 Overall Control COAG p 
No. participants 78 38 40  





71.9 ± 9.4 <0.001 
Female No. (%) 46 (59%) 
22 
(57.9%) 
24 (60%) 0.85 
Ethnicity     





37 (92.5%)  





2 (5%)  
     African origin No. (%) 1 (1.3%) 0 (0%) 1 (2.5%)  






0.09 ± 0.12 0.092 
IOP (mmHg) (Mean ± SD) 
16.4 ± 
4.42 
17.5 ± 2.5 15.3 ± 5.5 0.024 






0.72 ± 2.81 0.53 






1.01 ± 0.93 0.13 
HFA SAP SITA 24-2 









DC, Dioptric Cylinder; DS, Dioptric Sphere; MD, Mean Deviation; PSD, Pattern 
Standard Deviation; SAP, Standard automated perimetry: SD, Standard deviation. 
 
Figure 3.10 shows a histogram of the mean log flicker thresholds for the control 
and COAG subgroups with their 95% confidence intervals. As disease severity 
increased, there was a rise of the mean log threshold for flicker detection. There 
was overlap in the distribution for control participants and those with early COAG. 
Consequently, the test failed to identify almost half (n=6, 46%) of patients with early 
COAG, while correctly identifying 93% and 100% of moderate and severe COAG 
respectively. Lowering the log threshold could increase sensitivity at a cost of 




Figure 3.10. Histogram of the mean log thresholds of control and glaucoma subgroups. 
Glaucomatous visual field loss was classified using Hodapp-Parrish Anderson criteria 
















A4FTp vs FDT p < 1% any point 
missed 
0.08 -0.03 to 0.18 0.15 
A4FTp vs FDT p < 5% any point 
missed 
0.09 -0.02 to 0.02 0.12 
A4FTp vs SD-OCT p < 1% 0.07 -0.04 to 0.18 0.18 
A4FTp vs SD-OCT p < 5% 0.01 -0.11 to 0.12 0.91 
 
Table 3.3 shows a comparison of the AUROC curves between the three index 
tests. No statistically significant differences where identified between the A4FTp 
and FDT p < 1% level or FDT p < 5% level. A comparison between the A4FTp and 
the SD-OCT RNFL (any quadrant) at the p < 1% level or p < 5% level also failed 
to identify any statistically significant differences. 
The mean AUROC for the three tests were; A4FTp (0.824, 95% confidence interval 
(0.726-0.921)), SD-OCT (any RNFL parameter p<1% level) (0.898 (0.830-0.966)) 
and FDT (one or more locations missed at p<5% level) (0.911 (0.824-0.963)). 
 
Figure 3.12. Venn diagram of best performing parameter from the index tests in identifying 
the COAG cases alone or combined with the other tests.  
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Figure 3.12 shows a Venn diagram for the best performing criteria of each index 
test for detecting COAG participants. The numbers within the circles represent the 
number of participants identified by each test. The A4FTp detected slightly fewer 
COAG cases (n=33, 83%) than the FDT (n=36, 90%) or SD-OCT (n=35, 88%). All 
three index tests failed to defect two cases (5%). The diagram reveals that 
combining a structural test (SD-OCT) with a functional test (FDT or A4FTp) 
increases the likelihood of detecting the disease. 
 
Figure 3.13. Likert responses from user acceptability survey 
 
Figure 3.13 shows the Likert scores from the tests from the acceptability survey. 
The A4FTp, FDT and SD-OCT had a similar proportion of participants (>90%) 
rating the tests as not uncomfortable or not too long. Of the four tests the HFA was 
flagged as uncomfortable, too long and difficult to perform by comparison. Although 
the A4FTp was considered comfortable and relative short some participants found 




Strengths and limitations of the study 
Determination of diagnostic accuracy is a key step in the development of a new 
screening test. Diagnostic accuracy is the ability of a test to differentiate between 
patients who have the condition of interest (target condition) and those who do not. 
The accuracy of the test is evaluated by comparing the results of the test with an 
established diagnostic reference standard on the same series of participants. 
Although the case-control design used in the current study is likely to overestimate 
diagnostic accuracy, it is a convenient first stage in the evaluation of a new test. 
The design also allows for an assessment of the comparative accuracy of the new 
test with more established screening tests for COAG.  
The A4FTp has a number of advantages, including its ease of administration and 
interpretation, a relatively short testing time and robustness to the effects of fixation 
losses, media opacity or refractive error. Since flicker sensitivity is less affected by 
age than standard automated perimetry (Tyler 1989; Lachenmayr et al 1994), we 
did not attempt to age match the cases and controls. Consequently, there was a 
statistically significant difference in the mean age of the two groups. Although we 
cannot exclude the possibility that this baseline age difference may have impacted 
on the observed difference in flicker sensitivity between groups, the same 
confounder would have applied to the FDT used for the comparative analysis. 
Another potential limitation of the A4FTp was its failure to detect 6 out of the 12 
patients with early glaucoma. The initial design of the A4FTp tested a small number 
of locations to detect those with more advanced visual field loss, on the basis that 
those at higher risk of significant visual disability in their lifetime would generally 
present with greater field damage at presentation (Saunders et al., 2014). A test 
strategy could potentially be developed to improve the ability of the A4FTp to detect 
early glaucoma by using smaller stimuli and further test locations. 
 
Conclusion 
Based on a comparison of the AUROC curve, the overall performance of the 
A4FTp was similar to the FDT (C20-5 algorithm) and the SD-OCT (RNFL thickness 
outside normal limits). The best performing criterion for the A4FTp was the mean 
threshold of all four stimulus locations. The optimal threshold criterion for the 
A4FTp was based on an equal weighting for sensitivity and specificity. Using this 
criterion, the test identified 33 out of the 40 glaucoma cases in our sample (83%). 
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Test accuracy for all index tests was equivalent for the detection of COAG. Time 
taken to complete the A4FTp was relatively short and initial results are promising.  
User acceptability of the A4FTp was positive, with similar acceptability 
questionnaire scores to the FDT and SD-OCT, in terms of comfort and participant’s 
opinion on the duration of the test. Although some participants found the A4FTp 
difficult to perform, this was generally related to issues relating to identifying the 
appropriate key on the keypad corresponding to the location of the presented 
stimulus. However, further refinement and optimisation of the A44FTp in the future 
could include the use of touch screen technology, which would remove the need 
for the keypad. 
 
3.6. Role in the study 
Professor Christopher Tyler wrote the original code in MATLAB for the stimulus 
algorithm. Under Professor Tyler’s supervision, I coded the version of the algorithm 
used in the A4FTp, including stimulus size, location, input configuration, working 
database and output files. I then designed the validation study, recruited 
participants, collected data, and analysed the data in consultation with Professors 
Tyler and Lawrenson. The preliminary findings were reported via poster at BCOVS 
2015 before the subsequent diagnostic accuracy study was performed. The 
diagnostic accuracy study was conducted jointly with another PhD student (Anish 
Jindal) under Professor Lawrenson’s supervision. The findings were reported at 
the European Association for Vision and Eye Research (EVER) meeting in 2018.  
My role in this part of the study included data collection, analysis and I jointly 
drafted the submitted manuscript to Ophthalmic and Physiological Optics with 
Anish Jindal. 
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Diagnostic accuracy of structural and functional tests for 
the detection of sight-threatening eye diseases in a 
community setting 
 
4.1. Background  
The burden of sight loss disproportionally affects the elderly (Evans and Rowlands, 
2004) with one in five people aged 75 or over and one in two people aged 90 and 
over suffering from visual impairment (RNIB 2009). Sight loss from cataract, 
chronic open angle glaucoma (COAG), age-related macular degeneration (AMD), 
diabetic retinopathy and uncorrected refractive error affects approximately 2 million 
of the United Kingdom (UK) population (Pezzulo et al, 2018). Current case-finding 
strategies have been shown to miss half of the population affected by conditions 
such as COAG (Tielsch et al, 1991; Klein et al, 1992; Mitchell et al, 1996; Quigley 
and Vitale, 1997; Wensor et al, 1998). Poor access to routine NHS sight testing in 
‘at risk’ populations, coupled with the absence of symptoms in the early stages of 
many of these diseases can lead to delayed or late presentation (Boodhna and 
Crabb, 2015; Lane et al, 2015). 
Given that a significant proportion of sight loss can be prevented through early 
detection and timely therapeutic interventions, it is likely that investment in 
prevention and screening for sight-threatening eye disease would lead to a 
reduction in the burden of visual disability (WHO 2013). Currently the only sight 
threatening eye disease that satisfies the Wilson and Jungner’s criteria (Wilson 
and Jungner, 1968) for a screening program in the UK is diabetic retinopathy, 
conditions such as glaucoma or macular degeneration, although fulfilling most 
criteria are not considered to be cost effective. (Hopley et al, 2004; Burr et al, 
2007). 
Earlier studies have investigated the diagnostic accuracy of individual screening 
tests to detect sight-threatening eye disease in general or clinic-based populations 
and established that no single test has sufficient accuracy (Ariyasu et al, 1996; 
Wang et al, 1998; Ivers et al, 2001; Boland et al, 2016). Recent studies have shown 
that by combining screening tests diagnostic performance can be significantly 
improved. For example, Kopplin and Mansberger demonstrated that a battery of 
tests of ocular structure and function performed by ophthalmic technicians were 
105 
 
effective in the detection of visually significant eye disease in a population of 
American Indian and Alaskan Native participants (Kopplin and Mansberger, 2015). 
The primary objective of this study was to determine the diagnostic accuracy of 
modern imaging and visual function testing technologies, used alone and in 
combination, for detecting chronic open angle glaucoma (COAG) compared to a 
reference standard ophthalmic examination that included standard automated 
perimetry (SAP). We also conducted an exploratory secondary analysis to 
determine the performance of combinations of the screening tests for detecting 






Recruitment of participants 
This prospective diagnostic accuracy study was conducted in a University 
community eye clinic in London between September 2012 and September 2013. 
Men and women aged ≥60yrs were invited to participate via a written invitation sent 
to community groups and local optometry practices. There were no exclusion 
criteria and participants with pre-diagnosed ocular disease were included. 
Participants underwent a series of technology-based index tests followed by a 
reference standard ophthalmic examination, conducted on the same day, to 
establish ocular health status. The study was approved by the School of Health 
Sciences Research and Ethics Committee, City, University of London and adhered 
to the tenets of the Declaration of Helsinki. Informed written consent was obtained 
prior to participation. All subjects underwent a series of technology-based index 
tests carried out by the author (BF), followed by a reference standard ophthalmic 
examination, conducted by an experienced clinician (PD), who had been 
independently validated in glaucoma and medical retina by sub-specialist 
ophthalmologists at Moorfields Eye Hospital. 
The study was designed and reported in accordance with the Standards for 







Figure 4.1. Study Flow Diagram. The number of eye conditions exceeds the number of 
participants due to co-morbidity. Abbreviations: AREDS=Age-related Eye Disease Study; 
FDT=Frequency Doubling Technology Perimetry; SD-OCT=Spectral Domain Optical 
Coherence Tomography; ORA=Ocular Response Analyzer; AMD=Age-related macular 
degeneration: COAG=Chronic Open Angle Glaucoma. 
 
Description of index tests 
Frequency Doubling Technology perimeter 
The frequency doubling illusion was initially reported by Kelly in 1966 (Kelly, 1966). 
The frequency doubling effect occurs when a low spatial frequency sinusoidal 
grating undergoes high temporal frequency flicker in counter phase. This causes 
the grating to appear to be twice its actual spatial frequency. Frequency doubled 
stimuli were incorporated in the first generation ‘Frequency Doubling Technology 
(FDT) perimeter in 1997, as a means of screening for glaucomatous visual field 
defects (Johnson and Samuels, 1997). This first-generation instrument used 10° 
targets and incorporated both supra-threshold and threshold screening algorithms. 
The C20-5 supra-threshold algorithm initially presents stimuli at a contrast level 
that can be detected by 95% of the normal age matched population. If the stimuli 
are seen, the test locations are classified as within normal limits. Targets missed 
at the 95% level are then retested at contrast levels that 98% and 99% of the age-
marched normal population can detect. The depth of any defect can therefore be 




In the current study, a first generation FDT perimeter was used in the C20-5 supra-
threshold mode. An abnormal result was defined using 2 cut-offs: 
• ≥1 location(s) missed at the P < 5% significance level 
• ≥1 location(s) missed at the P < 1% significance level 
Further analysis of the FDT output can be performed using a scoring system 
described by Patel et al. (Patel et al., 2000). The algorithm allocates an overall 
score for each FDT result giving increased importance to more severe defects and 
locations missed closer to fixation (Patel et al, 2000). Figure 4.2 shows the point 
score for each stimulus location. The final score can be determined by adding 
scores for all missed points with scores ranging from 0 to 87. 
 
 
Depth of defect Significance level Multiplying factor 
Within normal limits P ≥ 5% 0x 
Mild relative loss P < 5% 1x 
Moderate relative loss P < 2% 2x 
Severe loss P < 1% 3x 
Figure 4.2. Patel et al., 2000 scoring algorithm of FDT supra-threshold results 
 
Moorfields Motion Displacement Test  
The Moorfields Motion Displacement Test (MMDT), which was developed 
collaboratively by Moorfields Eye Hospital, London, the UCL Institute of 
Ophthalmology and City, University of London, is a supra-threshold test for 
detecting sensitivity loss across the field of vision in glaucoma (Ong et al., 2014). 
The test uses 31 moving line stimuli that are displayed on a standard laptop 
computer at test locations corresponding to the 24-2 pattern of the Humphrey 
Visual Field Analyser (HFA). Peripheral stimuli are scaled in size by estimates of 
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retinal ganglion cell density, and with respect to age and eccentricity. The subject 
is positioned at 30cm using a purpose-built chin rest and stand. 
Each line is subjected to a brief period of horizontal oscillation at a frequency of 
approximately 5 Hz in a random sequence. Whilst maintaining central fixation, the 
observer is asked to indicate whenever they detect any line movement. The 
subject’s responses are then compared to a normative database and the results 
are recorded on a pass-fail probability plot (Figure 4.3) that provides an estimate 
of the ‘probability of true damage’ (PTD) at each test location between 0 and 100. 
A higher global PTD representing a greater probability of visual field damage. In 
this study, an abnormal plot was defined by the developers’ recommended 
threshold of a global PTD≥3.0. 
 
 





IVue Spectral domain OCT  
Optical coherence tomography (OCT) is an imaging technique that uses the 
principle of low-coherence interferometry to generate high resolution cross-
sectional images of ocular structures. The development of Spectral or Fourier 
domain (SD) technology allowed faster image acquisition, higher image resolution, 
and improved retinal layer segmentation compared with the previous time-domain 
systems (TD) (Schuman, 2008). 
The iVue spectral domain OCT (SD-OCT) is a smaller, portable version of the 
larger RTVue OCT that provides a range of retinal and optic nerve scans with 
normative database comparisons (Figure 4.4). For the current study, we extracted 
data from the following scans: 
• Nerve Fibre Optic nerve head (ONH) scan provides retinal nerve fibre layer 
(RNFL) thickness measurements from a circular area of 4.93mm radius from 
the disc centre 
• iWellness screening protocol, which provides data on the integrity of the retina 
and optic nerve. The iWellness report provides 8 high resolution cross-
sectional images along with quantitative data on full retinal thickness and 
ganglion cell complex (GCC) thickness. 
A Scan Quality Index (SQI) below 40 generally represents a poor-quality scan, 
however the manufacturer advised that any decision to exclude data should also 
be based on a subjective evaluation of the scan. The first scan of the two captures 
was used for analysis unless it was excluded on the basis of poor quality (SQI <40 
and/ or subjective evaluation). Scans were initially captured in low light conditions 
to encourage pupil dilation and without the use of mydriatic agents. If media 
opacities or miotic pupils precluded capture of adequate quality data, imaging was 
repeated following pupil dilation  
The following structural parameters were included in the quantitative analysis 




Table 4.1. OCT structural parameters 
Parameter Description 
Optic nerve head peripapillary 
Retinal nerve fibre layer 
(ONH-RNFL) 
The segmentation algorithm of the iVue OCT 
detects the internal limiting membrane and 
outer border of the RNFL in each A-scan. RNFL 
thickness is extracted from a peripapillary 
annulus of data points, 3.45mm from the centre 
of the optic disc, to construct a peripapillary 
RNFL map, which is divided into 8 segments. 
Each segment is color-coded based on a 
comparison of the average thickness compared 
to the age-matched normative database.  
Ganglion cell complex (GCC) The ganglion cell complex (GCC) comprises the 
ganglion cell layer, together with the adjacent 
RNFL and inner plexiform layers. GCC 
thickness data is acquired from a 7mm by 7mm 
square area that is centred on the fovea. These 
data are compared to the normative database 
reference values and reported as within normal 
limits, borderline or outside normal limits 
Global loss volume (GLV) Measures the average GCC loss over the entire 
GCC map. 
Focal loss volume (FLV) Measurements of the average amount of focal 
loss over the entire GCC map. The FLV detects 
focal loss using a pattern deviation map, similar 
to the corrected pattern standard deviation in 
visual fields plots. 
Full retinal thickness Full retinal thickness is measured from the 7 x7 
mm macular scan and is presented as a retinal 
map showing the average retinal thickness in 
the nine areas as defined by the Early 








Figure 4.4. Vue SD-OCT scan outputs; iWellness (composite of GCC and retina map 
protocols) and ONH retinal nerve fibre layer thickness (RNFL) 
 
Ocular response analyser  
The Ocular Response Analyser (ORA) (Reichert Ophthalmic Instruments, Buffalo, 
NY) is a non-contact tonometer that measures the corneal response to indentation 
by a rapid air pulse. An alignment system positions an air tube over the central 
cornea and applies a 20ms collimated air pulse of increasing force to produce 
progressive corneal deformation. The cornea passes through an inward 
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applanation state (P1) to indentation, followed by an outward applanation state 
(P2), before returning to a normal corneal curvature (Figure 4.5). The air pulse 
force at P1 and P2 is used to calculate four parameters: 
• Two measures of corneal biomechanics; corneal hysteresis (CH) and corneal 
resistance factor (CRF). The former quantifies the viscoelastic mechanical 
damping ability of the cornea and the latter is thought to represent the corneas 
overall viscoelastic resistance. 
• Goldmann-correlated IOP (IOPg) and corneal-compensated IOP (IOPcc). 
IOPg is analogous to standard NCT IOP measurements, whereas IOPcc is an 
estimate that uses a mathematical correction to minimize corneal dependence 
of IOP and therefore provides a better indication of the true IOP (Lau and Pye, 
2011). 
A minimum of 4 measurements from each eye was taken. 
 
 
Figure 4.5. Ocular Response Analyser (ORA) graphical plot comprising 3 curves: pressure 
of air applied to the cornea (green), raw signal of applanation detection system (red), and 





Index test quality indicators and defined thresholds 
Quality/reliability indicators and thresholds to define abnormality were pre-defined 
for each index test (Table 4.2) 
 
Table 4.2. A summary of index test quality indicators and cut-offs used in the study 
Test 
Indicators of suitable quality 
data 
Cut-off / threshold for 




False positives (FP) < 15% 
Fixation errors (FE) < 15% 
≥ 1 location missed at 5% level 
≥ 1 location missed at 1% level 
MMDT 
False positives (FP) < 15% 
Late responses (LR) < 15% 
Global PTD ≥ 3.0 
iVue SD-
OCT 
Scan quality index (SQI) ≥ 40 and 
subjective evaluation of scans 
P < 1% as defined by the 
normative database 
ORA Waveform score (WS) ≥ 6.5 
Corneal hysteresis (CH) < 9.1 
Corneal resistance factor  






Reference standard examination 
The reference standard examination was conducted on the same day as the index 
tests and the clinician was masked to the index test results. 
The reference standard ophthalmic examination included: 
• Full ophthalmic and medical history (with positive family history of 
glaucoma recorded if the subject reported a first-degree relative diagnosed 
with glaucoma) 
• Measurement of visual acuity (using a 3m logMAR chart) 
• Anterior segment assessment by biomicroscope (with eyes that had a 
potentially occludable angle identified by the van Herick test evaluated by 
gonioscopy and following pupil dilation the LOCS II system was used to 
grade nuclear, cortical, and subcapsular cataract) 
• Measurement of IOP by the Goldmann applanation tonometer 
• Dilated fundus examination (including a detailed optic disc examination) 
using indirect ophthalmoscopy with the slit-lamp 
• Fundus photography (Topcon TRC-NW8F retinal camera) 
• HFA used in 24-2 SITA standard mode (repeat testing was attempted for 
unreliable results and Glaucoma hemifield test (GHT) recordings of ‘outside 
normal limits’, either on the same day after a rest period or arranged for 
another day within a month of the study visit) 
The following diagnostic criteria were used for classification of subjects as COAG 
and each of the potentially sight-threatening conditions that were included in the 
current analysis (Table 4.3). 
Validation of the reference standard examiner 
There is accumulative evidence that specialist optometrists, following additional 
training and accreditation, can make appropriate diagnostic and clinical 
management decisions when compared with a subspecialist ophthalmologist 
(Reeves et al 2016; Creer et al 2019; Harper et al 2020). The reference standard 
examiner for the current study was an experienced optometrist (PD) who 
undertook a clinical placement in glaucoma clinics at Moorfields Eye Hospital, 
London followed by an accreditation assessment. The accreditation assessment 
consisted of comparing diagnostic decisions with the classification of a consultant 
ophthalmologist (DGH or WN) on 50 patients. Each patient was classified as 
‘normal’, ‘suspect glaucoma’, or ‘glaucoma’ based on the combined observation of 
the optic disc using binocular indirect ophthalmoscopy and visual field results. The 
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same classification system was used for further evaluation of the ability to classify 
glaucoma subjects by visual field assessment alone using 100‐HFA C24‐2 
threshold field plots (50 right and 50 left eye plots). Results were compared with 
classification by a glaucoma consultant (DGH). 
For accreditation in medical retinal conditions, the reference standard examiner 
attended the Moorfields Reading Centre for training and certification for grading 
ophthalmic images for diabetic retinopathy and age related macular degeneration. 
For training in diabetic retinopathy, the UK National Diabetic Retinopathy screening 
grading guidelines were used along with the Early Treatment of Diabetic 
Retinopathy Study standard images. PD initially graded the training images 
(minimum of 100 images of different quality and severity) and after achieving the 
required competency, was tested on batches of 25 sets of images to achieve the 
necessary accreditation. For Age Related Macular Degeneration, PD undertook 
training using the Wisconsin Age Related Macular Degeneration Study Folders, 
which show characteristic changes of all aspects of AMD stages. Once the 





Table 4.3. Diagnostic criteria used for classifying the most prevalent eye diseases. 
Abbreviations: AREDS=Age-related Eye Disease Study; COAG=Chronic open 
angle glaucoma; LOCS II=Lens Opacities Classification System II.  






1. Open anterior chamber angle  
2. Localized absence of neuroretinal rim, 
cup-to-disc ratio ≥0.7, or interocular 
asymmetry in vertical cup-to-disc ratio 
≥0.2 in similar sized discs 
3. Presence of a concordant 
glaucomatous field defect based on 
criteria amended from Hodapp, Parrish 
and Anderson§ 
Suspect 
Features of glaucomatous optic 
neuropathy but with normal or equivocal 
fields or subjects with glaucomatous 






Microaneurysms, dot blot haemorrhages, 
Venous loops, cotton wool spots  
Pre-proliferative 
retinopathy (R2) 
Venous beading, venous reduplication, 
multiple blot haemorrhages, intraretinal 
microvascular abnormality (IRMA) 
Proliferative 
retinopathy (R3) 
Active proliferative retinopathy  
Maculopathy (M1) 






Early AMD (AREDS 
category 2) 
Several small drusen or a few medium-
sized drusen in one or both eyes 
Intermediate AMD 
(AREDS category 3) 
Many medium-sized drusen or one or 
more large drusen (≥125µm), in one or 
both eyes 
Advanced AMD  
(AREDS category 4) 
Geographic atrophy of the RPE involving 





LOCS II grading*** 
LOCS II score ≥2.0 for cortex, posterior 
subcapsular, nuclear, or hypermature 
cataract 
§ - Hodapp et al 1993 - Clinical decisions in glaucoma 
* - The grading system for diabetic retinopathy was based on that used by the UK 
NHS Diabetic Eye Screening Programme. 
https://www.gov.uk/government/publications/diabetic-eye-screening-retinal-
image-grading-criteria 
** - The grading system for AMD was based on the classification system used in 
AREDS (Ferris et al 2005 - A Simplified Severity Scale for Age-Related Macular 
Degeneration: AREDS Report No. 18) 




Index test acceptability questionnaire 
Whilst the pupils were dilating, subjects were asked to complete a questionnaire 
regarding the acceptability of each of the index tests in terms of difficulty to perform, 
comfort and test duration using the form below (Figure 4.6). A full sized version of 
the questionnaire is available in Appendix 2. 
 
 
Figure 4.6. Index test acceptability questionnaire 
 
Sample size calculation 
The sample size was determined based on the primary outcome of the study, which 
was to determine the diagnostic accuracy of the index tests to detect COAG. This 
required an estimation of anticipated sensitivity of the tests, acceptable precision 
of the estimate and the prevalence of the condition in the local population. For a 
sensitivity of 0.75 (Mowatt et al, 2008), with a minimal acceptable precision of the 
sensitivity estimate of ±0.25 with 0.95 probability, we calculated that we would need 
approximately 50 cases of COAG. A previous cross-sectional study of an elderly 
population in North London (Reidy et al, 1998), found a prevalence of suspected 
and definite COAG of approximately 10%. We therefore estimated that 500 
subjects needed to be recruited. 
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For the secondary analysis, we prospectively determined that a similar number of 
cases of intermediate and advanced AMD would be required, based on a disease 
prevalence of 8% in the target population (Reidy et al, 1998), anticipated index test 




Statistical analyses were performed using the following software: SPSS v21.0 
(www.ibm.com/SPSS_Statistics), Medcalc v18.0 (www.medcalc.org) and STATA 
13.0 (StataCorp LP, College Station, TX, www.stata.com). Unreliable results from 
visual function tests (FDT and MMDT) and repeatedly poor-quality data from the 
ORA and OCT were removed from the analysis. 
Primary analysis: index test performance for the detection of COAG 
For the initial analysis of test performance, summary statistics were tabulated and 
standard measurements of diagnostic accuracy (sensitivity, specificity, positive 
and negative predictive values) were calculated using 2 x 2 tables. 
To compare index test performance within a clinically relevant range for detection 
of a low-prevalence disease, we determined the sensitivity at 90% specificity and 
normalised the partial area under the receiver operating characteristic curves 
(AUROC) to determine the average sensitivity between 90% and 100% specificity. 
To test for any statistically significant differences between sensitivities at a set 
specificity and differences in partial AUROC curve estimates, the Wald test was 
used (Pepe et al, 2009). 
Secondary analysis: index test performance for the detection of sight-threatening 
eye disease 
For the secondary analysis we adopted the statistical methods previously reported 
by Kopplin and Mansberger (Kopplin and Mansberger, 2015). Binomial logistic 
regression was used to identify univariate and multivariate associations between 
index test results and sight-threatening eye diseases. We also evaluated the 
predictive value of best-corrected visual acuity (<6/12). Those tests with univariate 
associations were included as potential covariates in a multivariate model using 
stepwise logistic regression. A significance level of <0.05 was set for entering and 
retaining each covariate in the final multivariate model. The diagnostic 




Analysis of user acceptability 
Numerical data were grouped into summary tables based on the subject’s 
response to the user acceptability survey, which asked them to rate agreement or 
disagreement with statements relating to particular characteristics of each test 
using a 7-point Likert scale. ‘Disagree’ was denoted by scores=1 to 3, ‘neither 





4.3. Summary of main results 
Demographic and clinical characteristics of the study population 
Table 4.4 describes the demographic characteristics of the 505 participants. This 
was a predominantly white population with proportionally more females than males 
(approx. 60:40). A significant proportion of the population suffered from diabetes 
(12.3%). A family history of glaucoma was reported by 16.4% of subjects. 
 
Table 4.4. Demographic data for the 505 participants 
 All subjects 
N (%) 505 (100) 
Age (years) 
Median (IQR) 
68.0 ± 9 



















Positive family history of glaucoma (%) 83 (16.4) 
Diabetes (type 1 or type 2) (%) 62 (12.3) 
 
Table 4.5. provides a detailed summary of the ocular pathologies identified by the 
reference ophthalmic examination. Unsurprisingly, in this elderly population, a high 
proportion of participants had ocular morbidities. We adopted a strict definition for 
definitive COAG, which included both disc damage and a corresponding visual field 
defect. Twenty-six subjects (5.1%) fulfilled these criteria with a further 32 ‘COAG 
suspects’ (6.4%), consisting of those with a suspicious disc or showing a field 
defect consistent with glaucoma but with an equivocal disc appearance. Of the 26 
definite COAG cases, 11 (42%) were classified as early, 6 (23%) were classified 
as moderate, and 9 (35%) were classified as advanced using the criteria defined 
by Hoddap et al (Hoddap et al, 1993). 
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Other ocular pathologies identified in the cohort, which may or not have been 
mutually exclusive, included 9.5% subjects with intermediate or advanced AMD, 
10.7% with clinically significant cataract in one or both eyes and 7.3% with diabetic 
retinopathy. 
Table 4.5. Ocular pathology identified by the reference standard examination. 
Abbreviations: AMD=Age-related Macular Degeneration; COAG=Chronic 
open angle glaucoma; CHRPE= Congenital hypertrophy of retinal pigment 
epithelium. 
 
Condition N (%) 
AMD 
     Early 
     Intermediate 








     Non-proliferative 
     Pre-proliferative 
     Proliferative 










     Suspect 







Ocular hypertension (OHT) 17 (3.4) 
Cataract (clinically significant) 54 (10.7) 
Other Retinal pathology 
     Retinal detachment or tear (previous) 
     Choroiditis 
     Pigmented fundus lesion (naevus, CHRPE) 
     Chorioretinal atrophy/degeneration 















Other macular pathology 
     Macular hole (lamellar or full thickness) 
     Epiretinal membrane: clinically significant 









Other optic disc disorders 4 0.8 
Corneal pathology 19 3.8 
Corneal refractive surgery 9 1.8 
Vitreal body opacity 10 2 
Anterior segment disorder 
     Primary angle closure suspect/ Primary angle closure 
     Pigment dispersion/ pseudo exfoliation 









Neurological disorder 6 1.2 






Diagnostic accuracy of screening tests 
Detection of COAG 
Test performance was evaluated using the individual as the unit of analysis. Test 
thresholds at pre-defined cut-offs were compared for the most abnormal index test 
result from the right or left eye to the overall reference standard classification 
(Table 4.6). 
Using an FDT threshold of one or more points missed at a P< 5% level of 
significance yielded a sensitivity of 92.3% and specificity of 65.2% for the detection 
of definite COAG. Test specificity improved to 79.1% using a criterion of one or 
more location(s) missed at a P < 1% with a similar level of sensitivity (88.5%). 
The MMDT was evaluated using 2 different threshold criteria, using a PDT ≥ 2 as 
a cutoff threshold yielded a sensitivity of 69.2% and specificity of 77.5%, a second 
assessment with a PDT ≥ 3 resulted on a sensitivity of 65.4% and specificity of 
81.2%. 
We evaluated the performance of individual OCT parameters that fell outside the 
99% normal limit for the detection of COAG (Table 4.6). All RNFL and GCC 
parameters performed well. The best performance was achieved using a criterion 
of an abnormality in any RNFL or GCC parameter, which yielded a sensitivity of 
96.1% and specificity 81.3%.  
A proportion of those with definite COAG had been previously diagnosed and were 
therefore already on ocular hypotensive therapy. Consequently, the IOP values 
recorded with the ORA had little diagnostic value for distinguishing those subjects 
with COAG from the rest of the sample. 
The performance of index tests for detecting definitive and suspect COAG 
combined was variable (data not shown), with sensitivities ranging from 10.3% for 








Table 4.6. Sensitivity and specificity of index tests for detection of definite COAG 
Index test parameter Sensitivity (%) (CI) Specificity (%) (CI) 
FDT 1 point missed at P<5% 
level 
92.3 (75.9 - 97.9) 65.2 (60.8 – 69.3) 
FDT 1 point missed at P<1% 
level 
88.5 (71.0 – 96.0) 79.1 (75.2 – 82.5) 
MMDT PDT ≥ 2 69.2 (50.0 – 83.5) 77.5 (73.5 – 81.0) 
MMDT PDT ≥ 3 65.4 (46.2 – 80.6) 81.2 (77.5 – 84.5) 
   
OCT Any RNFL 88.5 (71.0 – 96.0) 88.7 (85.5 – 91.2) 
OCT Any GCC 80.8 (62.1 – 91.5) 87.9 (84.7 – 90.6) 
OCT Any (GCC or RNFL) 96.1 (81.1 – 99.3) 81.3 (77.5 – 84.6) 
   
ORA IOPg 19.2 (8.5 – 37.9) 88.9 (85.8 – 91.4) 
 
Sensitivity at 90% specificity and partial AUROC curves for the range 90% to 
100% specificity are summarized in Table 4.7 
Table 4.7. Sensitivity at 90% specificity and Partial area under the receiver 
operation characteristic curve (AUROC) of index tests for detection of COAG 
Index test parameter 
Sensitivity at 90% 
specificity (%) (CI) 
Partial AUROC from 
90% to 100% 
Specificity (CI) 
FDT Patel score 61.5 (39.4 – 83.6) 0.35 (0.18 – 0.52) 
MMDT Global PDT 55.7 (37.4 – 78.0) 0.44 (0.26 – 0.61) 
   
OCT Mean RNFL 65.4 (47.1 – 83.7) 0.58 (0.41 – 0.76) 
OCT RNFL Inferior 
quadrant 
82.8 (67.6 – 97.9) 0.70 (0.53 – 0.86) 
OCT Mean GCC 65.4 (47.1 – 83.7) 0.51 (0.34 – 0.67) 
OCT GCC Inferior 
hemifield 
69.2 (51.4 – 87.0) 0.61 (0.44 – 0.77) 
OCT GCC – FLV 61.5 (42.4 – 80.7) 0.43 (0.27 – 0.59) 
   
ORA IOPg 19.2 (3.9 – 34.6) 0.15 (0.02 – 0.27) 
 
The inferior quadrant RNFL thickness was the best-performing OCT parameter, 
providing the highest sensitivity (82.8%) for the detection of COAG at 90% 
specificity and a partial AUROC of 0.70 from 90% to 100% specificity. The inferior 
quadrant RNFL thickness was statistically significantly superior to the FDT (Patel 






Figure 4.7. Index test diagnostic effectiveness comparisons using receiver operating 
characteristic curves with sensitivity at set specificity estimates and associated 95% 
confidence intervals for detection of COAG. FDT = Frequency Doubling Technology 
Perimeter; MMDT = Moorfields Motion Displacement Test; RNFL = retinal nerve fibre layer 
thickness. 
 
Detection of any sight-threatening eye disease 
Given the high prevalence of potentially sight-threatening eye disease in our 
elderly population, we conducted an exploratory secondary analysis to determine 
the predictive value of the index tests to identify any sight-threatening eye disease. 
For the purposes of this analysis sight-threatening eye disease was defined as: 
clinically significant cataract, suspect or definite COAG, intermediate or advanced 
AMD and significant diabetic retinopathy (see Table 4.3 for diagnostic definitions). 
In total 168 (33.5%) of the cohort met this definition. The performance of the 
individual screening tests for each of these conditions is shown in Table 4.8. 
Diagnostic precision of the individual tests was generally poor with sensitivities to 
detect any sight threatening disease ranging from 16.1% (IOP) to 61.9% (FDT 
<5%). 
Univariate and multivariate logistic regression was used to determine the 
association between abnormal screening test results and the presence of sight-
threatening eye disease. The impact of adding best-corrected visual acuity <6/12 
from the reference test to the model was also evaluated and the diagnostic 
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performance of the final multivariate subset of screening tests was calculated. 
Table 4.9 shows the results of the multivariate regression analysis, which identified 
that visual acuity <6/12, abnormal FDT (≥1 point missed at 5% level) and 
peripapillary RNFL thickness outside the 99% normal limit were most predictive of 
any sight-threatening eye disease. The 3 screening tests had a sensitivity of 61.3% 





Table 4.8. Sensitivity and Specificity of individual screening tests for each Eye Disease 
Screening test 
 Visual Acuity < 6/12 IOP FDT 1% Level FDT 5% Level 
 Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
Clinically significant 
cataract 
42.6% 90.0% 16.7% 86.3% 46.3% 78.0% 64.8% 65.2% 
AMD 37.5% 89.1% 12.5% 85.8% 45.8% 77.7% 60.4% 64.3% 
COAG (Definite and 
suspect) 
22.4% 87.7% 19.0% 86.6% 62.1% 80.3% 72.4% 66.4% 
COAG (Definite) 38.5% 87.9% 19.2% 86.2% 88.5% 78.9% 92.3% 64.9% 
Significant diabetic 
retinopathy 
37.5% 86.9% 25.0% 86.1% 62.5% 76.1% 75.0% 62.6% 
Any of the above 26.8% 93.2% 16.1% 86.9% 46.4% 86.4% 61.9% 73.9% 
 
 SD-OCT (Full Retinal or GCC thickness) 
SD-OCT (Full Retinal 
thickness) 
SD-OCT (GCC thickness) 
SD-OCT (Peripapillary 
RNFL thickness) 
 Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
Clinically significant 
cataract 
42.6% 66.5% 35.2% 71.9% 25.9% 84.9% 13.0% 91.8% 
AMD 52.1% 67.4% 50.0% 73.4% 37.5% 85.9% 25.0% 93.0% 
COAG (Definite and 
suspect) 
60.3% 68.9% 53.4% 74.4% 50.0% 88.1% 44.8% 96.0% 
COAG (Definite) 76.9% 67.9% 65.4% 73.2% 80.8% 87.2% 69.2% 94.5% 
Significant diabetic 
retinopathy 
87.5% 66.4% 87.5% 72.1% 12.5% 83.6% 0.0% 91.1% 





Table 4.9. Multivariate Stepwise Logistic Regression Analysis of Abnormal Screening Results with Ocular Disease. Abbreviations: CI -Confidence 





















OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Visual acuity 
<6/12 
5.53 (2.91, 10.54) NS NS 4.49 (2.40, 8.41) NS 4.12 (2.26, 7.52) 
IOP>21mmHg NS NS NS NS NS NS 
FDT ≥1 point 
missed at 1% 
level 
NS 8.55 (2.22, 32.96) 3.93 (2.05, 7.53) NS NS NS 
FDT ≥1 point 
missed at 5% 
level 
2.60 (1.40, 4.84) NS NS NS NS 3.62 (2.38, 5.51) 
SD-OCT (GCC 
thickness) 
NS 5.52 (1.57, 19.41) NS NS NS NS 
SD-OCT (Full 
retinal thickness) 




NS 9.10 (2.85, 28.96) 11.98 (5.61, 25.60) 3.81 (1.74, 8.35) NS 5.24 (2.45, 11.24) 
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Table 4.10. Diagnostic performance of the optimised panel of screening tests 
(SD-OCT, FDT and measurement of visual acuity in identifying sight-threatening 
eye disease) 
 Value (95% CI) 
Sensitivity 61.3% (53.5–68.7) 
Specificity 78.8% (74–83.1) 
Positive Likelihood Ratio (PLR) 2.9 (2.3–3.7) 
Negative Likelihood Ratio (NLR) 0.5 (0.40–0.60) 
Disease Prevalence 33.7% (29.6–39.1) 
Positive Predictive Value (PPV) 59.5% (53.7–65.2) 
Negative Predictive Value (NPV) 80.0% (76.6–83.0) 
Overall Accuracy 72.9% (68.8–76.8) 
 
 
Figure 4.8 shows Venn diagrams combining index tests for the detection of COAG 
(Figure 4.8A) and any sight-threatening condition (Figure 4.8B). All 26 subjects 
with definite COAG were identified by the combination of peripapillary inferior 
RNFL thickness outside 99% confidence interval and an abnormal FDT (1 or more 
points missed lat the 5% level). In terms of any sight-threatening disease, the 
combination of an abnormal FDT, RNFL thickness outside 99% confidence limits 
and VA <6/12 identified 121 (72%) of those affected by the most severe disease. 
In the 47 subjects where 3 tests were recorded as normal; these 11 were 
diagnosed with cataract, 14 with non-proliferative diabetic retinopathy, 8 with 



















Figure 4.8. Venn diagrams presenting combined index test results for identification A) 





Participant acceptability of screening tests 
 
Figure 4.9. Aggregated Likert scale responses to index test acceptability survey in response to the statements a) ‘Test was uncomfortable’, b) ‘Test was too 
long’, and c) ‘Test was difficult to undertake’
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
FDT Test uncomfortable
FDT Test too long
FDT Test difficult to undertake
MMDT Test uncomfortable
MMDT Test too long
MMDT Test difficult to undertake
HFA Test uncomfortable
HFA Test too long
HFA Test difficult to undertake
iVue OCT Test uncomfortable
iVue OCT Test too long
iVue OCT Test difficult to undertake
ORA Test uncomfortable
ORA Test too long
ORA Test difficult to undertake
Likert responses from user acceptability survey from all participants 
Disagree Neither agree nor disagree Agree
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Figure 4.9 summarises aggregated Likert scale responses to the user 
acceptability survey. Overall, all index tests were well received with respondents 
finding that the tests were comfortable, not too long, and easy to perform. About 
5% of respondents found that visual function tests (FDT and MMDT) were 
‘uncomfortable’, ‘too long’ or ‘difficult to undertake’. By contrast, 14% and 26% of 
respondents found the HFA was difficult to undertake or too long respectively. 
At the end of the survey 216 (43%) subjects responded to the ‘additional 
comments’ box. Responses were coded into three main categories:  
• Responses relating to screening tests 
• Responses relating to researchers 
• Other comments.  
 
Of the 139 comments relating to test experience, 74 (53%) were classified as 
‘positive’ and 54 (39%) ‘negative’. The majority of the negative comments (65%, 
24 of 37) made reference to the HFA followed by the FDT (19%, 7 of 37). General 
comments in the ‘negative’ group referred to tests being ‘tiring/ difficult’ (n=5), the 







The overall aim of this study was to evaluate the diagnostic performance of 
modern structural and visual function screening tests for the detection of sight 
threatening eye conditions in a representative sample of elderly subjects, 
recruited from the community. The results of the screening tests, used alone or 
in combination, were evaluated against a reference standard ophthalmic 
examination, conducted by a trained clinician, who had been independently 
validated in the diagnosis of glaucoma and medical retinal conditions in the HES. 
We also investigated the acceptability to patients of each screening test to 
determine their suitability in this population. 
Our initial objective was to determine the diagnostic accuracy of the technologies 
for glaucoma case-finding. Differentiating between COAG, suspect COAG and 
normal subjects presents a significant diagnostic challenge, due to the substantial 
overlap of clinical characteristics between these groups. There is also the 
problem of confounding due to other ocular pathologies that are likely to be 
present in an elderly population. Independent analyses were performed for those 
with manifest COAG (meeting a strict diagnostic definition based on disc 
appearance and corresponding glaucomatous field loss), and an analysis of a 
combined population of COAG cases and those with suspect COAG. Diagnostic 
accuracy was assessed using predefined cut-offs for abnormality and estimates 
of sensitivity, specificity, and likelihood ratios were calculated. We also derived 
estimates of sensitivity at 90% specificity and partial areas under the receiver 
operating characteristic curve (AUROC) from 90% to 100% specificity, to 
compare index test performance within a clinically relevant range for detection of 
a low-prevalence disease. Subjects were also asked to complete a questionnaire 
regarding the acceptability of each index test. 
Overall, all index tests were well received with over 90% of respondents finding 
that the tests were comfortable, not too long, and easy to perform. The OCT was 
the most effective in identifying subjects with glaucoma. Using a criterion of any 
OCT parameter outside the 99% level, we would have identified 25 out of the 26 
subjects diagnosed with definite COAG. In terms of individual OCT parameters, 
the inferior RNFL thickness showed the greatest diagnostic accuracy, with a 
sensitivity of 77% and specificity of 95%. Furthermore, inferior RNFL thickness 
was associated with a significantly greater partial AUROC than any of the visual-
function tests. This probably reflects the increased vulnerability of the inferior 
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quadrant of the optic disc to glaucomatous damage (Jonas et al. 1993; Hood et 
al 2013). 
All index tests showed poor discrimination between normal subjects and COAG 
suspects. Although we were able to show an improved sensitivity based on failure 
on either a structural or functional test, this was at the expense of a significantly 
reduced specificity. For case-finding of suspect COAG, we therefore propose a 
Bayesian strategy. This is based on the principal that in routine clinical practice, 
a clinician will intuitively integrate the results of several diagnostic tests together 
with a judgement of the patient’s pre-test probability of COAG to determine 
likelihood of disease. The post-test probability can be formally calculated using 
widely available Bayesian diagnostic algorithms, which require the pre-test 
probability of disease and the likelihood ratios of the individual diagnostic tests 
used (Fagan 1975, Garway-Heath & Friedman 2003). 
In 1968, Wilson and Jungner outlined ten criteria for appraising the viability, 
effectiveness and appropriateness of a screening programme (Wilson and 
Jungner, 1986). Although COAG fulfils criteria relating to the condition, availability 
of screening tests and treatment, in high-income countries, population screening 
for glaucoma is not considered to be cost-effective (Burr et al 2007; Moyer 2013). 
The cost-effectiveness of screening could be improved by combining screening 
tests to enhance diagnostic performance and also include more than one sight-
threatening condition into the screening programme. We therefore conducted an 
exploratory reanalysis of our data to determine the performance of combinations 
of structural and functional screening tests to identify any sight-threatening eye 
disease. For the purposes of the current study we defined sight-threatening eye 
disease as: clinically significant cataract, actual or suspect COAG, intermediate 
or advanced AMD and significant diabetic retinopathy.  
Using logistical regression, we established that the combination of reduced visual 
acuity (VA <6/12), abnormal FDT, and peripapillary RNFL thickness outside 99% 
normal limits had the best overall discriminatory power for the detection of any 
sight-threatening eye disease, with a sensitivity estimate of 61% and specificity 
79%. The optimised test combination showed similarly high positive and negative 
predictive values to a previously published study conducted in Native Alaskans 
and American Indians (Kopplin and Mansberger 2015). The screening panel 
could form the basis of a screening model where the tests could be performed by 
a trained technician and screen positive individuals referred for further 
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investigation. Such a strategy could be particularly effectively in underserved 
populations with poor access to eye care.  
In conclusion, this study provides useful preliminary data to inform the 
development of further larger, multicentre screening studies to validate this 
screening panel. 
 
Strengths and limitations of the study 
This study is the first of its kind in the UK to evaluate the performance of a 
combination of screening tests to detect clinically significant eye diseases in a 
primary care setting.  
The major strengths in the study are:  
• The design, analysis, and reporting complied with the STARD guidelines 
(Standards for Reporting of Diagnostic Accuracy)  
• The target population included consecutive subjects who met the 
inclusion criteria and there were no exclusions, this was intended to 
reduce spectrum bias. 
• The prevalence of sight-threatening eye diseases in our population was 
calculated around 30%, this value was similar to a London-based cross-
sectional study that used random sampling (Reidy et al, 1998). 
• The reference standard used to classify the participants ocular status 
corresponded to that used in a typical hospital eye clinic and was based 
on the results of a standard ophthalmic examination by a validated 
clinician.  
• The reference standard examination and all index tests were performed 
on the same day and the clinician performing the reference standard 
examination and the ophthalmic technician undertaking the index tests 
were masked to each other results. 
The study limitations: 
• Although the population included consecutive subjects who met the 
inclusion criteria it is possible that higher numbers of those with a personal 
or family history of eye disease were more likely to agree to participate in 
the study. 
• The sample size of 505 subjects provided between 2% to 10% of subjects 
with a specific sight threatening eye condition. The small number of 
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patients with those conditions resulted in wide CIs around our diagnostic 
sensitivity estimates. 
• Roughly 90% of our study population was of white European origin and 
therefore our findings may not be generalizable to other ethnic groups.  
• The current study did not include a formal cost-effectiveness analysis 
• We used a pragmatic diagnostic reference standard, similar to the 
standard expected in specialist glaucoma and medical retina clinics in the 
UK. To this end, the reference examiner undertook an extensive process 
of training and accreditation using a standard methodology to ensure that 
they reached the required standard. A definitive reference standard would 
have required a dedicated Reading Centre with trained and accredited 





4.5. Role in the study 
My role in this study included conducting all index tests (FDT, MMDT, OCT and 
ORA) on the 505 participants. Another PhD student (Priya Dabasia) carried out 
the reference standard ophthalmic examination. I established the database for 
storage of index and reference test results and combined the data for the 
analysis. Working with Priya, I was involved in cleaning and checking the data 
and as part of the research team, contributed to data analysis and interpretation. 
For the publication of the results of the primary analysis ‘Diagnostic Accuracy of 
Technologies for Glaucoma Case-Finding in a Community Setting 
(Ophthalmology 2015; 122:2407-2415) Priya drafted the manuscript and the 
results of this study were included as part of her PhD (A study of the role of 
advanced technologies in glaucoma case-finding). 
Under Professor Lawrenson’s supervision I was involved in the conception, 
design, data analysis and interpretation for the secondary objective (role of 
advanced technology in the detection of sight-threatening eye disease in a UK 
community setting). The findings were reported via poster at EVER 2019 and 
subsequently published in BMJ Open Ophthalmology. I wrote the first draft of this 
paper and subsequent revisions following input from members of the research 
team.  
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Summary of results and directions for future work 
5.1. Summary 
The work presented in this thesis describes a programme of research that 
encompassed the use of diagnostic tests evaluating ocular structure or function 
for the detection of COAG and other sight-threatening eye conditions. The work 
was disseminated in 4 peer reviewed publications (Fidalgo et al 2015, Dabasia 
et al 2015; Fidalgo et al 2018; Fidalgo et al 2019). 
Diagnostic accuracy studies evaluate the ability of one or more ‘index tests’ to 
correctly classify patients as having a particular target condition, which is defined 
by an appropriate ‘reference standard’. In 2003, reporting standards for this type 
of study design were developed and widely disseminated (Bossuyt et al 2003). 
The purpose of the Standards for Reporting of Diagnostic Accuracy Studies 
(STARD) checklist was to allow authors, journal editors and peer-reviewers to 
ensure that all relevant information is included in diagnostic accuracy studies.  In 
parallel, an evidence-based methodological quality assessment tool (QUADAS) 
was developed (Whiting et al 2003) to assist systematic reviewers of diagnostic 
accuracy studies to evaluate risk of bias of studies included in the review. 
Chapter 2 describes the quality of reporting and overall methodological quality of 
diagnostic accuracy studies that used perimetry to detect functional vision loss in 
glaucoma. Additionally, we investigated the impact of the publication of the 
STARD reporting standards on the quality of reporting by comparing articles 
published before and after the development and dissemination of the STARD 
checklist in 2003. 
STARD compliance was poor with only 50% of the items adequately reported. Of 
all included articles in the study only 3 reported the use of the STARD checklist 
in the development of the paper. Less than 20% of journals recommend the use 
of STARD when reporting diagnostic accuracy studies compared to 50% of the 
same journals advising the use of CONSORT for the reports of RCTs. It is unclear 
whether the poor adoption of STARD by ophthalmology journals is the primary 
reason for the incomplete reporting of diagnostic accuracy studies identified in 
this study, however the requirement for authors to complete the STARD checklist 
prior to manuscript submission should be promoted. 
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Chapter 3 describes the development and diagnostic performance of a novel 
screening test that could potentially be used in conjunction with other clinical tests 
to detect COAG in a primary care setting. The Accelerator 4-Alternative Forced-
Choice Flicker Test prototype (A4FTp) measures temporally-modulated flicker 
thresholds in regions of the visual field with high susceptibility to glaucomatous 
loss. We initially evaluated the psychometric properties of the A4FTp in 20 normal 
subjects who were tested multiple times over a period of 3 months. In addition, 4 
randomly selected subjects underwent a total of 10 repetitions to study test-retest 
repeatability and learning effects. We showed that the A4FTp threshold algorithm 
with the shorter staircase termination criterion (T8) enabled rapid determination 
of flicker sensitivity in susceptible regions of the visual fields. Thresholds were 
repeatable and did not show any statistically significant learning effect over 
multiple repetitions.  
To determine the diagnostic accuracy of the A4FTp, we compared the ability of 
the test to identify patients with COAG from a sample of 78 participants that 
included 40 subjects with COAG and 38 normal controls. The performance of the 
A4FTp was compared with Frequency Doubling Technology (FDT) perimetry 
(C20-5 programme) and iVue Spectral Domain Optical Coherence Tomography 
(SD-OCT).  The accuracy of each test was determined by analysis of the area 
under the receiver operator characteristic curve (AUROC). 
We found that test accuracy for the A4FTp was comparable with the FDT and 
SD-OCT for the detection of COAG. The results of this study demonstrated that 
with further refinement, the A4FTp could potentially have a future role in 
glaucoma detection. 
Visual impairment disproportionately affects the elderly due to the increased risk 
of sight-threatening eye disease with age. Given that a high proportion of sight 
loss is preventable, there is a compelling case for early detection and referral for 
timely therapeutic intervention. Previous studies have found that no single test 
has sufficient predictive power to detect sight-threatening eye disease.  
Chapter 4 describes the evaluation of the diagnostic performance of a number 
of visual function and structural tests for the detection of COAG and other sight-
threatening eye disease in a representative sample of elderly subjects. Five 
hundred and five subjects underwent 4 index tests conducted by the author, who 
was unaware of subjects’ ocular status. FDT and MMDT were used in supra-
threshold mode. iVue SD-OCT measured GGC and RNFL thickness. The 
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diagnostic reference standard was full ophthalmic examination by an experienced 
clinician who was masked to index test results. The SD-OCT was the most 
effective in identifying subjects with COAG. Our results showed we would have 
identified 25 out of the 26 subjects diagnosed with definite COAG. The inferior 
RNFL thickness showed the greatest diagnostic accuracy, with a sensitivity of 
77% and specificity of 95%. In a secondary analysis of the data, we also 
established that the combination of reduced visual acuity (VA <6/12), abnormal 
FDT, and peripapillary RNFL thickness outside 99% normal limits had the best 
overall discriminatory power for the detection of any sight-threatening eye 
disease, with a sensitivity estimate of 61% and specificity 79%, with similarly high 
positive and negative predictive values. The results provide useful data to inform 
the development of larger, multicentre population studies to evaluate the 
effectiveness and cost-effectiveness of screening for eye disease in the elderly. 
 
5.2 Directions for future work 
Since completing the work on Chapter 2 updated versions of STARD and 
QUADAS have been published (Whiting et al 2011; Bossuyt et al 2015). 
Consequently, future updates of the systematic review should utilise these 
updated standards. It is unclear whether simply highlighting poor reporting will 
lead to continuing improvements in methodological quality and standards of 
reporting of studies of diagnostic test accuracy. It may require lobbying of journal 
editors to update their guidance to authors to include reference to STARD. Most 
journals currently require adherence to CONSORT guidelines for the publication 
of RCTs.  
The work described in Chapter 3 showed the potential of a new screening test for 
COAG, detection. This proof of concept study demonstrated that moderate to 
advanced COAG could be effectively detected using a small number of 
strategically placed flicker stimuli. Further development of the A4FTp is likely to 
involve optimisation of stimulus size number and location. This would be followed 
by the development of an appropriate normative database for the perimeter.  
Although the algorithm was able to quickly determine flicker thresholds at the four 
test locations, the use of a supra-threshold strategy would further reduce test 
times. A supra-threshold strategy may be more appropriate for case-finding in the 
general population. We are currently in the process of optimising the A4Ftp on a 
touch screen tablet display to increase its portability. 
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The results described in Chapter 4 showed the good predictive power of a small 
battery of screening tests to identify sight-threatening eye disease. Although we 
were able to recruit a relatively large sample of elderly subjects that were broadly 
representative of the population to be screened, the prevalence of the individual 
target conditions was low, which led to wide confidence intervals around the 
sensitivity and specificity estimates of test performance. Increasing the sample 
size would improve the precision around these estimates and also potentially 
provide greater ethnic diversity. Furthermore, the panel of screening tests 
identified in the set of subjects in the current study should also be independently 
verified on a separate validation sample to assess the generalisability of the 
findings. In parallel, a health economic analysis could be undertaken to 
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Katz 1993 5341 
Humphrey full 
field 120 
Optic disc examination, IOP 
and SAP 





Wishart, 1993 56 OKP 
Optic disc examination and 
SAP 
Adachi, 1994 855 Noise field test 

















Optic disc examination, IOP 
and SAP 





Optic disc examination, IOP 
and SAP 





Optic disc examination, IOP 
and SAP 
Huang 1998 148 Dicon SAP 
Sim 1999 479 SAP 
Optic disc examination, IOP 
and gonioscopy 
Yamada 1999 240 
FDT 
Damato 
Optic disc examination, IOP 
and SAP 
Burnstein 2000 29 FDT SAP 
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Cello 2000 484 FDT 
Optic disc examination, IOP 
and SAP 
Fabre 2000 48 
TOP 
FDT 
Optic disc examination, IOP 
and SAP 
Racette 2000 212 SWAP 
Optic disc examination, IOP 
and SAP 




Optic disc examination and 
IOP 
Vitale 2000 249 Dicon 
Optic disc examination and 
gonioscopy 
Paczka 2001 253 FDT 
Optic disc examination, IOP 
and SAP 
Bayer 2002 72 
SWAP 
FDT 
Optic disc examination and 
IOP 
Horn 2002 639 FDT 
Optic disc examination, 
gonioscopy and IOP 
Iwasaki, 2002 14814 FDT 
Optic disc examination and 
SAP 




Optic disc examination, 
gonioscopy and IOP 
Horn, 2003 307 FDT 
Optic disc examination, 
gonioscopy, IOP and SAP 
Detry-Morel 2004 1620 FDT 
Optic disc examination and 
IOP 
Babalola 2005 298 
Motion 
sensitivity 
Optic disc examination and 
IOP 
Brusini 2005 123 Rarebit 
Optic disc examination, 
gonioscopy and IOP 




evaluation and SAP 
Heeg 2005 452 FDT SAP 
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Mansberger 2005 93 FDT 
Optic disc examination and 
IOP 
Robin 2005 704 FDT 
Optic disc examination, IOP 
and SAP 






Optic disc examination and 
IOP 
Brusini 2006 318 
FDT N-30 
Matrix 30-2 
Retinal nerve fiber layer 
(RNFL) and Optic disc 
examination 
Gardiner 2006 218 FDT 
Optic disc examination and 
SAP 




Retinal nerve fiber layer 
(RNFL), Optic disc 
examination, IOP and OCT 
North 2006 100 FDT 
Optic disc examination, IOP, 
gonioscopy and SAP 





Optic disc examination, 
gonioscopy and IOP 





Optic disc examination and 
IOP 
Ferreras 2007 294 
SWAP 
FDT 
Optic disc examination, IOP 
and SAP 
Fortune 2007 185 SAP 
Optic disc examination and 
output of the Moorfields 





Horn 2007 109 
FDT 
SWAP 
Optic disc examination, IOP, 
gonioscopy, SAP and 
papillometry 
Iwase 2007 2892 FDT 
Optic disc examination, IOP, 
gonioscopy and SAP 















Optic disc examination, 
gonioscopy and IOP 
Spry 2007 53 
FDT 24-2-5 
FDT N-30-5 
Optic disc examination, 
gonioscopy and IOP 
Wang 2007 4349 FDT Optic disc examination 
Cook 2009 105 FDT 
Ophthalmological 
examination 
Salim 2009 70 FDT IOP, optic disc examination 




Optic disc examination, 
gonioscopy and IOP 
Toth 2009 181 Matrix FDT 
Optic disc examination, IOP, 
gonioscopy and SAP 
Rowe 2010 197 Damato 
Optic disc examination and 
SAP 




Optic disc examination and 
SAP 
Zhong, 2010 160 SWAP 
Optic disc examination, 
gonioscopy and IOP 
Francis 2011 6082 FDT 
Optic disc examination, 
gonioscopy and IOP 
Gonzalez 2011 328 
Pulsar 
FDT 
Optic disc examination, SAP 
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Kamdeu, 2011 550 FDT 
Optic disc examination, 
gonioscopy and IOP 




SAP, optic disc 
examination, optical 
coherence tomography 
(OCT) and IOP 




Optic disc examination, SAP 
Horn 2014 171 FDF 
SAP, optic disc 
examination, OCT, 
gonioscopy and IOP 
Kanadani 2014 95 FDT 
Optic disc examination, IOP, 
gonioscopy and SAP 










Optic disc examination, IOP, 
gonioscopy, fundus 
photography and SAP 
Ghazali 2015 518 SAP 






Optic disc examination, IOP 
and SAP 
Rosen 2015 130 PERCEPT 
Optic disc examination, IOP, 
gonioscopy and SAP 
Boland et al, 2016 6797 FDT Fundus photography 
Mwanza 2016 224 FDT 
Optic disc examination, IOP 
and SAP 
Olsen 2016 97 DMCO 
Optic disc examination and 
SAP 
Johnson et al, 
2017 
206 VFE 




Takahashi 2017 141 
G-Dynamic 
and GST 
Optic disc examination and 
SAP 




Optic disc examination, IOP 
and gonioscopy 














Optic disc examination and 
IOP 
Fidalgo 2018 78 A4FTp, FDT 
Optic disc examination, IOP, 
gonioscopy and SAP 
Olsen 2018 627 DMCO 
Optic disc examination, IOP, 
gonioscopy and SAP 




Optic disc examination and 
SAP 
Abbreviations: A4FTp - Accelerator 4-Alternative Forced-Choice Flicker Test 
prototype; DAP - Detection acuity perimetry; DMCO - Damato multifixation 
campimetry; EMP - Eye Movement Perimetry; FDF – Flicker defined form; FDT 
– Frequency doubling technology; HRP - High-pass resolution perimetry; 
MMDT – Moorfields motion displacement test; MP – microperimetry; OCT - 
Optical coherence tomography; ORA – Ocular response analyser; OKP - 
Oculo-kinetic perimetry; PP - Pulsar perimetry; RAP - Resolution acuity 
perimetry; RBP – Rarebit perimetry; SAP – Standard automated perimetry; 
SWAP - Short Wavelength Automated Perimetry; TMP - Temporal modulation 





Appendix 2.  
A4FTp flicker algorithm 
function FlickerScreen(f,n) 
% Two-screen version of a 4-patch peripheral flicker testing program 
% Control screen should not be visible to test subject 
% After first run, set windows to be non-overlapping on control screen 
% To run, choose 'Screening' or 'Choose Frequency' at the prompt 
% Screening starts the flicker at a moderate level suitable for patients 
% Choose frequency starts the flicker close to normal thresholds 
% Fixate the central dot and press any key to start 
% Press the 1, 2, 4 or 5 key on the number pad to match the flicker location 
% If no flicker seen, press the same key as for the previous trial 
% If unsure, press 0 to repeat same levels (but different location) 
% Press q + RETURN to quit 
% If program crashes, type Screen('CloseAll') and rerun program 
% For City system, change line 16 to PsychToolBox call, and activate line 42 
% Figure 1 shows the actual waveform presented on each trial (black trace) 
% and at 10x scale for visibility of the waveform at low amplitudes (green trace) 
% The results are for upper left, upper right, lower left and lower right 
% Results should be accurate to about +/- 1 decilog 






% Choose screen with maximum id - the secondary display: 
%screens=Screen('Screens') 
%screenid = max(Screen('Screens')); 
%screenid=Max(Screens); 
screenid = 0; %Change value to 2 to force presentation on second (144 Hz) 
screen 
 
% Open a fullscreen onscreen window on that display, choose a background 
% color of 128 = gray with 50% max intensity: 
%win = Screen('OpenWindow', screenid, 128, rect, [], [], [], [], imagingMode); 
 
cumpc=[1 0 0 0] 
 
if isempty(which('Screen')) 





if nargin < 1 









if nargin < 2 




 n = 10; 
end 
 
% Close previous figure plots: 
close all; 
 
% Make sure this is running on OpenGL Psychtoolbox: 
AssertOpenGL; 
% maxcount=60; %Screen refresh rate 
maxcount=120; %Screen refresh rate 




% load RESULTS 
load Patients 
dn=numel(Patients); 




% while numel(details1)>FlickerPatientNumberinput 
%     FlickerPatientNumberinput=input('Patient Number does not exist - 0 for 





 name=input('Name ','s'); 
 dob=input('DoB (DD/MM/YYYY) ','s'); 













viewingeye=input('Eye (L/R) ','s'); 









f=60 %Temporal frequency 
% f=input('Flicker frequency (5/10/15/30/60)? ','s') 





% Initial stimulus params for the stimulus patches: 
res = 1*[323 323]; 
sc = 300; %space constant 
border=50;%width of black border 
inc=0.27; %staircase increment - 0.27 is 0.1 log unit 
%inc=0; %staircase increment - 0.27 is 0.1 log unit 
dec=inc/2; %staircase decrement 
NumTrials=120; %maximum number of trials 
n=8; %number averaged 
gamma=1.9; 
pcInit=30; %Initial percent contrast 
 
 
% Disable synctests for this quick demo: 
oldSyncLevel = Screen('Preference', 'SkipSyncTests', 0); 
 
tw = 1200; 
th = 900; 
% x=tw/2;   
% y=th/2; %Centre of screen 
x=tw/3;  y=th/3;  
 
white=WhiteIndex(0); black=BlackIndex(0); 
%Using gray-0.5 as the mean level puts the mean halfway between two steps 
%Butit cannot match the steady level, so cannot be used 
%we will have to rely on using high frequencies with threshold > 1 step. 
 
% bgLum = 0.25; 
% gray=floor(bgLum*white+(1-bgLum)*black);  
gray=floor((white+black)/2);  
 




Screen('FrameOval',win,0,OffsetRect(CenterRect([1 1 40 40],wRect),-
Eyefield*120,0)); 
Screen('FrameOval',win,[0,0,0],OffsetRect(CenterRect([1 1 sc sc],wRect),-
Eyefield*x/2-Eyefield*120,y),4,4); %CWT 
Screen('FrameOval',win,[0,0,0],OffsetRect(CenterRect([1 1 sc sc],wRect),-
Eyefield*x/2-Eyefield*120,-y),4,4); %CWT 
Screen('FrameOval',win,[0,0,0],OffsetRect(CenterRect([1 1 sc 
sc],wRect),Eyefield*x-Eyefield*120,y/2),4,4); %CWT 





% Perform initial flip to gray background and sync us to the retrace: 
vbl = Screen('Flip', win,0); 
disp('Press any key to start') 
pause 
ts = vbl; 
tic; %test time start 
fig = figure('Position',[100 650 650 420]); 
 
%Psychophysics loop: Run to NumTrials: 
pc = pcInit*ones(1,4); 
cumpc=pc; 




 locKeys = '1739'; 
else 
 locKeys = '3917'; 
end 
 
locKeyIndex = zeros(1,numel(locKeys)); 
for i = 1:numel(locKeys) 





 framecount = 0; 
 locSwitch=round(0.5+rand*4); 
%    locSwitch=1; 
 switch locSwitch %CWT 
  case 1 
   loc = [-Eyefield*x/2-Eyefield*120,y]; 
  case 2 
   loc = [-Eyefield*x/2-Eyefield*120,-y]; 
  case 3 
   loc = [Eyefield*x-Eyefield*120,y/2]; 
  case 4 
   loc = [Eyefield*x-Eyefield*120,-y/2]; 





% tic %stym duration (Note this tick will overwrite the tic for the test 
% duration) 
 % Animation loop: 
 while framecount < maxcount*0.75 
  framecount = framecount + 1; 
  %Gabor temporal envelope around 'gray' with pc peak contrast 
  tc(framecount)=gray+pc(locSwitch)*exp(-((framecount-
maxcount/3)^2/((maxcount/6)^2)))*cos(2*pi*f*framecount/maxcount); %JAS: 
Gabor temporal envelope with pc peak contrast 







1 1 sc-8 sc-8],wRect),loc(1),loc(2))); %CWT 
  Screen('FrameOval',win,0,OffsetRect(CenterRect([1 1 40 
40],wRect),-Eyefield*120,0)); %Fixation spot 
 Screen('Flip',win,0,0,0); 
% WaitSecs(0.0144) 
 end %while framecount 







 hold on; plot((1:framecount)/maxcount,round(tc(1:framecount)),'k'); 
 axis([0 1 0 255]); drawnow 
 title('Black is true waveform, green is x10') 
 xlabel('Time (sec)')  
 ylabel('Luminance levels') 
 hold off 
   
 while 1 %checking for keypress 
  [KeyIsDown, endrt, KeyCode] = KbCheck; 
  if KeyIsDown 
   break; 
  end 
 end %while KBCheck 
  
 if KeyCode(locKeyIndex(locSwitch)) 
  pc(locSwitch)=max(1,pc(locSwitch)/(1+dec)); 
 elseif KeyCode(96) 
  %do not change values 
 elseif any(KeyCode(locKeyIndex)) 
  pc(locSwitch)=min(127,pc(locSwitch)*(1+inc)); 
 else 
%   q=input('Do you want to quit (q) or continue(c)?','s') 
  fprintf('Do you want to quit (q) or continue(c)?\n') 
  [~,KeyCode(:)] = KbWait(-3,2); 
  if KeyCode(KbName('q')) == 1 
   ListenChar(0) 
   Screen('CloseAll'); 
   cumpc 
   return 
  else 
   disp('CONTINUING') 
  end 
 end 
 cumpc=[cumpc;pc];  
 TrialNum=size(cumpc); 
 PCS{locSwitch}=[PCS{locSwitch};pc(locSwitch)]; 




 if sl>n 
  Amplitudes=[PCS{1}(end) PCS{2}(end) PCS{3}(end) 
PCS{4}(end)] 
  V(locSwitch)=std(log10(PCS{locSwitch}(sl-n+1:sl))); 
 end  
  
 if TrialNum(1)>NumTrials 
  ListenChar(0) 
  display('Run did not stabilize: Rerun') 
  Screen('CloseAll') 
 cumpc; 
  return 
 end %if 
  
end % while max(V)>0.15 
ListenChar(0) 
toc;%test time end 
testtime=toc; 
% cumpc=[FlickerPatientNumber 0 0 0; cumpc] 
% save cumpc 
 
NumberOfTrials=length(cumpc(:,1)); 
Thresholds=[PCS{1}(end) PCS{2}(end) PCS{3}(end) PCS{4}(end)]/1.27 
%Converts lut steps to percentage 
disp('(Minimum measurable threshold = 1)') 
% Decilog_Sensitivities=floor(log10(100./Thresholds)*10) 
disp('(Maximum measurable decilog sensitivity = 20 (= 2 log units) )') 













%The following lines save into the txt file the demographics data for the 



















% A final synced flip, so we can be sure all drawing is finished when we 
% reach this point: 






% Close window, release all resources: 
%Screen('CloseAll'); 





Appendix 3.  
Patient Acceptability Questionnaire 
 
Whilst the pupils were dilating, subjects were asked to complete a questionnaire 
regarding the acceptability of each of the index tests, attached bellow. 
      
         
Date of Examination:………………………      Subject ID SEC  ...…………….. 
   
 
Unless otherwise stated, please fill one circle for each question using 
black or blue ink 
For Questions 1 – 5, please indicate whether you agree or disagree with the 
statements relating to your views on the screening tests carried out on you 
today, using the nine-point scale provided.  
EXAMPLE:    
                                                                     Disagree                             Agree 
The screening test was uncomfortable     O                O       O       O       O       O 
 
Question 1: Humphrey visual fields (Location: small room on Level 4) – 




















O O O O O O O 
The test was too 
long 
O O O O O O O 
The test was 
difficult to 
undertake 
O O O O O O O 
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Question 3: FDT (Location: larger room on Level 6) – responding to flickering 
white and black bars 
 
 
Question 4: iVue OCT (Location: larger room on Level 6) – instrument captures 















O O O O O O O 
The test was 
too long 
O O O O O O O 
The test was 
difficult to 
undertake 










The screening test 
was 
uncomfortable 
O O O O O O O 
The test was too 
long 
O O O O O O O 
The test was 
difficult to 
undertake 















O O O O O O O 
The test was too 
long 
O O O O O O O 
The test was 
difficult to 
undertake 




Question 5: ORA (Location: larger room on Level 6) – ‘puff of air’ in the eye 
to measure your eye pressure 
Question 6 If you have any further comments on the acceptability of tests 
undertaken today, or on any other aspect of the study, please 


























O O O O O O O 
The test was too 
long 
O O O O O O O 
The test was 
difficult to 
undertake 
O O O O O O O 
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Appendix 4.  
Other published articles 
Fundus and OCT images collected as part of the work described in Chapter 4 
was used to study the diagnostic decision-making of UK community 
optometrists. This generated a further peer-reviewed publication on which I 
was a co-author. 
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